S&W Seed (SANW) 10-Q11 May 232023 Q3 Quarterly reportFinancial data

Company Profile

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Mar. 31, 2023	May 08, 2023
Cover [Abstract]
Entity Registrant Name	S&W SEED CO
Entity Central Index Key	0001477246
Document Type	10-Q
Document Period End Date	Mar. 31, 2023
Amendment Flag	false
Current Fiscal Year End Date	--06-30
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity File Number	001-34719
Entity Tax Identification Number	27-1275784
Entity Address, Address Line One	2101 Ken Pratt Blvd
Entity Address, Address Line Two	Suite 201
Entity Address, City or Town	Longmont
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80501
City Area Code	720
Local Phone Number	506-9191
Entity Common Stock, Shares Outstanding		42,963,993
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2023
Trading Symbol	SANW
Title of 12(b) Security	Common Stock, par value $0.001 per share
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Entity Incorporation, State or Country Code	NV
Document Quarterly Report	true
Document Transition Report	false

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2023	Jun. 30, 2022
CURRENT ASSETS
Cash and cash equivalents	$ 1,569,463	$ 2,056,508
Accounts receivable, net	20,424,589	19,051,236
Inventories, net	55,666,627	54,515,894
Prepaid expenses and other current assets	10,748,580	1,605,987
TOTAL CURRENT ASSETS	88,409,259	77,229,625
Property, plant and equipment, net	10,241,685	16,871,669
Intangibles, net	30,328,212	34,095,827
Right of use assets - operating leases	3,344,109	4,094,253
Equity method investments	24,121,771	367,970
Other assets	2,038,618	1,128,507
TOTAL ASSETS	158,483,654	133,787,851
CURRENT LIABILITIES
Accounts payable	17,441,428	15,901,116
Deferred revenue	1,411,651	605,960
Accrued expenses and other current liabilities	8,686,623	10,788,740
Current portion of working capital lines of credit, net	42,783,136	12,678,897
Current portion of long-term debt, net	1,058,051	8,316,783
TOTAL CURRENT LIABILITIES	71,380,889	48,291,496
Long-term working capital lines of credit, less current portion	0	21,703,286
Long-term debt, net, less current portion	3,648,732	3,992,540
Other non-current liabilities	2,575,442	3,587,041
TOTAL LIABILITIES	77,605,063	77,574,363
MEZZANINE EQUITY
Preferred stock, $0.001 par value; 3,323 shares authorized; 1,695 issued and outstanding at March 31, 2023 and June 30, 2022	5,154,079	4,804,819
STOCKHOLDERS' EQUITY
Common stock, $0.001 par value; 75,000,000 shares authorized; 42,914,070 issued and 42,889,070 outstanding at March 31, 2023; 42,608,758 issued and 42,583,758 outstanding at June 30, 2022	42,914	42,609
Treasury stock, at cost, 25,000 shares	(134,196)	(134,196)
Additional paid-in capital	167,297,153	163,892,575
Accumulated deficit	(84,598,398)	(105,873,557)
Accumulated other comprehensive loss	(6,908,157)	(6,560,600)
Non-controlling interests	25,196	41,838
TOTAL STOCKHOLDERS' EQUITY	75,724,512	51,408,669
TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' EQUITY	158,483,654	133,787,851
MEZZANINE EQUITY
MEZZANINE EQUITY
Preferred stock, $0.001 par value; 3,323 shares authorized; 1,695 issued and outstanding at March 31, 2023 and June 30, 2022	$ 5,154,079	$ 4,804,819

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2023	Jun. 30, 2022
STOCKHOLDERS' EQUITY
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	75,000,000	75,000,000
Common stock, shares issued	42,914,070	42,608,758
Common stock, shares outstanding	42,889,070	42,583,758
Treasury stock, shares	25,000	25,000
MEZZANINE EQUITY
SERIES B CONVERTIBLE PREFERRED STOCK
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	3,323	3,323
Preferred stock, shares issued	1,695	1,695
Preferred stock, shares outstanding	1,695	1,695

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Revenue	$ 17,662,307	$ 23,186,877	$ 50,465,974	$ 51,349,967
Cost of revenue	13,231,836	20,481,463	38,781,701	43,857,520
Gross profit	4,430,471	2,705,414	11,684,273	7,492,447
Operating expenses
Selling, general and administrative expenses	5,990,651	5,582,060	17,289,120	18,260,785
Research and development expenses	1,208,038	1,904,631	4,226,891	6,010,172
Depreciation and amortization	1,107,206	1,379,856	3,697,544	4,084,554
Loss (gain) on disposal of property, plant and equipment	37,325	49,796	32,914	13,957
Total operating expenses	8,343,220	8,916,343	25,246,469	28,369,468
Loss from operations	(3,912,749)	(6,210,929)	(13,562,196)	(20,877,021)
Other (income) expense
Foreign currency loss	331,889	146,935	699,428	567,963
Government grant income	(1,444,044)	0	(1,444,044)	0
Gain on sale of business interest	(38,323,506)	0	(38,323,506)	0
Gain on sale of equity investment	0	(68,967)	(32,030)	(68,967)
Gain on disposal of intangible assets	0	0	(1,796,252)	0
Change in contingent consideration obligation	0	(185,800)	0	(714,429)
Interest expense - amortization of debt discount	697,840	246,801	1,559,595	660,191
Interest expense, net	1,163,533	592,853	3,042,539	1,735,392
Other (income) expenses	1,641,406	(3,157)	1,601,697	(13,746)
Income (loss) before income taxes	32,020,133	(6,939,594)	21,130,377	(23,043,425)
Provision for (benefit from) income taxes	(500,118)	322,661	(884,078)	414,636
Income (loss) before equity in net earnings of affiliates	32,520,251	(7,262,255)	22,014,455	(23,458,061)
Equity in loss of equity method investees, net of tax	406,678	0	406,678	0
Net income (loss)	32,113,573	(7,262,255)	21,607,777	(23,458,061)
(Loss) income attributable to non-controlling interests	(5,792)	42,668	(16,642)	41,939
Net income (loss) attributable to S&W Seed Company	32,119,365	(7,304,923)	21,624,419	(23,500,000)
Net income (loss) attributable to S&W Seed Company	32,119,365	(7,304,923)	21,624,419	(23,500,000)
Dividends accrued for participating securities and accretion	(121,137)	(53,195)	(349,260)	(53,195)
Net income (loss) attributable to common shareholders	$ 31,998,228	$ (7,358,118)	$ 21,275,159	$ (23,553,195)
Net income (loss) attributable to S&W Seed Company per common share:
Basic	$ 0.75	$ (0.19)	$ 0.50	$ (0.62)
Diluted	$ 0.74	$ (0.19)	$ 0.50	$ (0.62)
Weighted average number of common shares outstanding:
Basic	42,790,693	39,515,547	42,681,201	38,240,917
Diluted	43,166,148	39,515,547	42,873,830	38,240,917

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ 32,113,573	$ (7,262,255)	$ 21,607,777	$ (23,458,061)
Foreign currency translation adjustment, net of income taxes	(172,782)	480,280	(347,557)	272,502
Comprehensive income (loss)	31,940,791	(6,781,975)	21,260,220	(23,185,559)
Comprehensive (loss) income attributable to non-controlling interests	(5,792)	42,668	(16,642)	41,939
Comprehensive income (loss) attributable to S&W Seed Company	$ 31,946,583	$ (6,824,643)	$ 21,276,862	$ (23,227,498)

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF MEZZANINE EQUITY AND STOCKHOLDERS' EQUITY (UNAUDITED) - USD ($)	Total	Preferred Stock	Common Stock	Treasury Stock	Additional Paid-In Capital	Accumulated Deficit	Noncontrolling Interests	Accumulated Other Comprehensive Loss
Beginning Balance, amount at Jun. 30, 2021	$ 74,393,193		$ 36,773	$ (134,196)	$ 149,684,357	$ (69,311,909)	$ (31,006)	$ (5,850,826)
Beginning Balance, shares at Jun. 30, 2021			36,772,983	(25,000)
Stock-based compensation, amount	1,821,808				1,821,808
Mezzanine equity Issuance of Series B convertible preferred stock, amount		$ 4,638,521
Mezzanine equity Issuance of Series B convertible preferred stock, shares		1,695
Mezzanine equity series B detachable warrant	12,919	$ 12,919
Series B detachable warrant	348,810				361,729	(12,919)
Mezzanine equity accrued dividends on Series B convertible preferred stock	40,276	40,276
Accrued dividends on Series B convertible preferred stock	(40,276)					(40,276)
Net issuance to settle RSUs, amount	(178,727)		$ 312		(179,039)
Net issuance to settle RSUs, shares			311,542
Proceeds from sale of common stock, net of fees and expenses, amount	10,657,774		$ 4,481		10,653,293
Proceeds from sale of common stock, net of fees and expenses, shares			4,481,243
Other comprehensive income (loss)	272,502							272,502
Net (loss) income	(23,458,061)					(23,500,000)	41,939
Ending Balance, amount at Mar. 31, 2022	63,817,023		$ 41,566	$ (134,196)	162,342,148	(92,865,104)	10,933	(5,578,324)
Ending Balance, shares at Mar. 31, 2022			41,565,768	(25,000)
Mezzanine Equity Ending Balance, amount at Mar. 31, 2022		$ 4,691,716
Mezzanine Equity Ending Balance, shares at Mar. 31, 2022		1,695
Beginning Balance, amount at Jun. 30, 2021	$ 74,393,193		$ 36,773	$ (134,196)	149,684,357	(69,311,909)	(31,006)	(5,850,826)
Beginning Balance, shares at Jun. 30, 2021			36,772,983	(25,000)
Issuance of common stock for cash upon exercise of stock options, shares	38,774
Mezzanine equity series B detachable warrant	$ 38,757
Mezzanine equity accrued dividends on Series B convertible preferred stock	127,541
Ending Balance, amount at Jun. 30, 2022	51,408,669		$ 42,609	$ (134,196)	163,892,575	(105,873,557)	41,838	(6,560,600)
Ending Balance, shares at Jun. 30, 2022			42,608,758	(25,000)
Mezzanine Equity Ending Balance, amount at Jun. 30, 2022	4,804,819	$ 4,804,819
Mezzanine Equity Ending Balance, shares at Jun. 30, 2022		1,695
Beginning Balance, amount at Dec. 31, 2021	64,160,529		$ 38,915	$ (134,196)	155,853,135	(85,506,986)	(31,735)	(6,058,604)
Beginning Balance, shares at Dec. 31, 2021			38,914,660	(25,000)
Stock-based compensation, amount	413,293				413,293
Mezzanine equity Issuance of Series B convertible preferred stock, amount		$ 4,638,521
Mezzanine equity Issuance of Series B convertible preferred stock, shares		1,695
Mezzanine equity series B detachable warrant		$ 12,919
Series B detachable warrant	348,810				361,729	(12,919)
Mezzanine equity accrued dividends on Series B convertible preferred stock	40,276	40,276
Accrued dividends on Series B convertible preferred stock	(40,276)					(40,276)
Net issuance to settle RSUs, amount	(20,440)		$ 18		(20,458)
Net issuance to settle RSUs, shares			18,056
Proceeds from sale of common stock, net of fees and expenses, amount	5,737,082		$ 2,633		5,734,449
Proceeds from sale of common stock, net of fees and expenses, shares			2,633,052
Other comprehensive income (loss)	480,280							480,280
Net (loss) income	(7,262,255)					(7,304,923)	42,668
Ending Balance, amount at Mar. 31, 2022	63,817,023		$ 41,566	$ (134,196)	162,342,148	(92,865,104)	10,933	(5,578,324)
Ending Balance, shares at Mar. 31, 2022			41,565,768	(25,000)
Mezzanine Equity Ending Balance, amount at Mar. 31, 2022		$ 4,691,716
Mezzanine Equity Ending Balance, shares at Mar. 31, 2022		1,695
Mezzanine Equity Beginning Balance, amount at Jun. 30, 2022	4,804,819	$ 4,804,819
Mezzanine Equity Beginning Balance, shares at Jun. 30, 2022		1,695
Beginning Balance, amount at Jun. 30, 2022	51,408,669		$ 42,609	$ (134,196)	163,892,575	(105,873,557)	41,838	(6,560,600)
Beginning Balance, shares at Jun. 30, 2022			42,608,758	(25,000)
Stock-based compensation, amount	1,381,898				1,381,898
Issuance of common stock for cash upon exercise of stock options	$ 997		$ 1		996
Issuance of common stock for cash upon exercise of stock options, shares	1,050		1,050
Mezzanine equity series B detachable warrant	$ 77,514	$ 77,514
Series B detachable warrant	(77,514)					(77,514)
Mezzanine equity accrued dividends on Series B convertible preferred stock	271,746	271,746
Accrued dividends on Series B convertible preferred stock	(271,746)					(271,746)
Subordinated loan & security agreement warrants	1,894,901				1,894,901
Net issuance to settle RSUs, amount	(25,663)		$ 202		(25,865)
Net issuance to settle RSUs, shares			201,807
Proceeds from sale of common stock, net of fees and expenses, amount	152,750		$ 102		152,648
Proceeds from sale of common stock, net of fees and expenses, shares			102,455
Other comprehensive income (loss)	(347,557)							(347,557)
Net (loss) income	21,607,777					21,624,419	(16,642)
Ending Balance, amount at Mar. 31, 2023	75,724,512		$ 42,914	$ (134,196)	167,297,153	(84,598,398)	25,196	(6,908,157)
Ending Balance, shares at Mar. 31, 2023			42,914,070	(25,000)
Mezzanine Equity Ending Balance, amount at Mar. 31, 2023	5,154,079	$ 5,154,079
Mezzanine Equity Ending Balance, shares at Mar. 31, 2023		1,695
Mezzanine Equity Beginning Balance, amount at Dec. 31, 2022		$ 5,032,942
Mezzanine Equity Beginning Balance, shares at Dec. 31, 2022		1,695
Beginning Balance, amount at Dec. 31, 2022	42,051,933		$ 42,788	$ (134,196)	165,444,354	(116,596,626)	30,988	(6,735,375)
Beginning Balance, shares at Dec. 31, 2022			42,788,423	(25,000)
Stock-based compensation, amount	619,892				619,892
Issuance of common stock for cash upon exercise of stock options	997		$ 1		996
Issuance of common stock for cash upon exercise of stock options, shares			1,050
Mezzanine equity series B detachable warrant		$ 25,838
Series B detachable warrant	(25,838)					(25,838)
Mezzanine equity accrued dividends on Series B convertible preferred stock	95,299	95,299
Accrued dividends on Series B convertible preferred stock	(95,299)					(95,299)
Subordinated loan & security agreement warrants	1,092,000				1,092,000
Net issuance to settle RSUs, amount	(12,714)		$ 23		(12,737)
Net issuance to settle RSUs, shares			22,142
Proceeds from sale of common stock, net of fees and expenses, amount	152,750		$ 102		152,648
Proceeds from sale of common stock, net of fees and expenses, shares			102,455
Other comprehensive income (loss)	(172,782)							(172,782)
Net (loss) income	32,113,573					32,119,365	(5,792)
Ending Balance, amount at Mar. 31, 2023	75,724,512		$ 42,914	$ (134,196)	$ 167,297,153	$ (84,598,398)	$ 25,196	$ (6,908,157)
Ending Balance, shares at Mar. 31, 2023			42,914,070	(25,000)
Mezzanine Equity Ending Balance, amount at Mar. 31, 2023	$ 5,154,079	$ 5,154,079
Mezzanine Equity Ending Balance, shares at Mar. 31, 2023		1,695

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES
Net income (loss)	$ 21,607,777	$ (23,458,061)
Adjustments to reconcile net income (loss) from operating activities to net
Stock-based compensation	1,382,895	1,821,808
Allowance for doubtful accounts	(76,575)	200,458
Inventory write-down	1,125,715	1,877,229
Depreciation and amortization	3,697,544	4,084,554
Loss on disposal of property, plant and equipment	32,914	13,957
Gain on disposal of intangible assets	(1,796,252)	0
Gain on sale of business interest	(38,323,506)	0
Gain on sale of equity investment	(32,030)	0
Equity in loss of equity method investees, net of tax	406,678	0
Government grant income	(1,444,044)	0
Change in deferred tax provision	(915,449)	0
Change in foreign exchange contracts	(167,688)	46,157
Foreign currency transactions	(1,320,052)	0
Change in contingent consideration obligation	0	(714,429)
Amortization of debt discount	1,559,595	660,191
Changes in:
Accounts receivable	(347,874)	(4,272,470)
Unbilled accounts receivable	(149,735)	0
Inventories	(2,961,203)	(10,256,441)
Prepaid expenses and other current assets	1,470,258	363,963
Other non-current assets	(786,506)	(152,621)
Accounts payable	1,868,140	8,866,376
Deferred revenue	806,691	2,670,287
Accrued expenses and other current liabilities	(1,438,490)	360,147
Other non-current liabilities	(27,198)	(117,524)
Net cash used in operating activities	(15,828,395)	(18,006,419)
CASH FLOWS FROM INVESTING ACTIVITIES
Additions to property, plant and equipment	(925,747)	(1,637,547)
Proceeds from disposal of property, plant and equipment	6,292	79,862
Net proceeds from sale of equity investment	400,000	988,504
Proceeds from partnership transaction	2,000,000	0
Capital contributions to partnerships	(119,897)	0
Proceeds from sale of business interest	7,000,000	0
Net cash provided by (used in) investing activities	8,360,648	(569,181)
CASH FLOWS FROM FINANCING ACTIVITIES
Net proceeds from sale of common stock	152,750	10,657,775
Net proceeds from sale of Series B convertible preferred stock	0	5,000,250
Taxes paid related to net share settlements of stock-based compensation awards	(25,663)	(178,727)
Borrowings and repayments on lines of credit, net	7,825,838	2,757,274
Borrowings of long-term debt	298,694	860,801
Debt issuance costs	(324,629)	(169,901)
Repayments of long-term debt	(1,361,496)	(1,027,959)
Net cash provided by financing activities	6,565,494	17,899,513
EFFECT OF EXCHANGE RATE CHANGES ON CASH	415,208	290,069
NET DECREASE IN CASH & CASH EQUIVALENTS	(487,045)	(386,018)
CASH AND CASH EQUIVALENTS, beginning of the period	2,056,508	3,527,937
CASH AND CASH EQUIVALENTS, end of period	$ 1,569,463	$ 3,141,919

General

General	9 Months Ended
General	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GENERAL	NOTE 1 - GENERAL The Company is a global multi-crop, middle-market agricultural company that is principally engaged in breeding, growing, processing and selling agricultural seeds. The Company operates seed cleaning and processing facilities, which are located in Texas, New South Wales and South Australia. The Company’s seed products are primarily grown under contract by farmers. The Company is currently focused on growing sales of their proprietary and traited products, improving margins through pricing and operational efficiencies, and developing the camelina market via a newly formed partnership. Investments and Partnership Activity Shell Partnership On February 6, 2023, S&W and Equilon Enterprises LLC (dba Shell Oil Products US, or Shell), entered into a partnership for the development and production of sustainable biofuel feedstocks through Vision Bioenergy Oilseeds LLC, or Vision Bioenergy. Under the terms of the partnership agreement, S&W contributed production and research facilities, along with certain personal property, including vehicles and other similar equipment, into its Vision Bioenergy subsidiary and subsequently sold a 66 % interest in the subsidiary to Shell. See Note 11 for further information. Trigall Australia Partnership Effective December 23, 2022, the Company’s wholly owned subsidiary, S&W Seed Company Australia Pty Ltd, or S&W Australia, entered into a partnership with Trigall Genetics S.A., or Trigall, for the development and marketing of wheat varieties in Australia. Under the terms of the partnership agreement, S&W Australia transferred certain intellectual property license rights and equipment into a wholly owned subsidiary and subsequently sold an 80 % interest in the subsidiary to Trigall. The subsidiary was renamed Trigall Australia Pty Ltd, or Trigall Australia. See Note 11 for further information. Bioceres Investment As of June 30, 2021, the Company held an investment in Bioceres, S.A., a provider of crop productivity solutions headquartered in Argentina. During the third quarter of fiscal year 2022, the Company sold 71.4 % of the investment in Bioceres, S.A. for net proceeds of $ 988,504 , which included a gain on the sale of marketable securities of $ 68,967 . The carrying value of the remainder of the investment was $ 367,970 at June 30, 2022, which was reported in Equity method investments on the Company's consolidated balance sheet. During the nine months ended March 31, 2023, the Company sold off the remainder of its investment in Bioceres, S.A. for net proceeds of $ 400,000 , which included a gain on the sale of equity investment of $ 32,030 . Basis of Presentation The accompanying condensed consolidated financial statements are unaudited and, in the Company’s opinion, include all adjustments, consisting of normal recurring adjustments and accruals, necessary for a fair statement of the Company’s consolidated balance sheets, statements of operations, comprehensive income (loss), cash flows and mezzanine equity and stockholders’ equity for the periods presented. Operating results for the periods presented are not necessarily indicative of the results to be expected for the full year ending June 30, 2023. Certain information and disclosures normally included in financial statements prepared in accordance with GAAP have been omitted in accordance with the rules and regulations of the SEC. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes included in the Annual Report on Form 10-K for the fiscal year ended June 30, 2022, as filed with the SEC. Certain prior period information has been reclassified to conform to the current period presentation. Operating lease right-of-use assets were reclassified from “Other assets” to “Right-of-use assets – operating leases” on the balance sheet in accordance with the disclosure guidance of ASC 842. Previously, the operating lease right-of-use assets were disclosed in the footnotes. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Estimates are adjusted to reflect actual experience when necessary. Significant estimates and assumptions affect many items in the financial statements. These include allowance for doubtful trade receivables, inventory valuation, the carrying value of the Company's equity investments, asset impairments, provisions for income taxes, grower accruals (an estimate of amounts payable to farmers who grow seed for the Company), contingencies and litigation. Significant estimates and assumptions are also used to establish the fair value and useful lives of depreciable tangible and certain intangible assets as well as valuing stock-based compensation. Actual results may differ from those estimates and assumptions, and such results may affect income, financial position or cash flows. The Company believes the estimates and assumptions underlying the accompanying condensed consolidated financial statements are reasonable and supportable based on the information available at the time the financial statements were prepared. However, certain adverse geopolitical and macroeconomic events, such as the ongoing conflict between Ukraine and Russia and related sanctions, and uncertain market conditions, including higher inflation and supply chain disruptions, have, among other things, negatively impacted the global economy, created significant volatility and disruption of financial markets, and significantly increased economic and demand uncertainty. These factors make many of the estimates and assumptions reflected in these condensed consolidated financial statements inherently less certain. Therefore, actual results may ultimately differ from those estimates to a greater degree than historically.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
Summary of Significant Accounting Policies	Mar. 31, 2023
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Liquidity and Going Concern Excluding the gain recognized in relation to the Vision Bioenergy partnership, the Company is not profitable and has recorded negative cash flows for the last several years. For the nine months ended March 31, 2023 , the Company reported net income of $ 21.6 million and net cash used in operations of $ 15.8 million. As of March 31, 2023 , the Company had cash on hand of $ 1.6 million. The Company had $ 1.8 million of unused availability from its working capital facilities as of March 31, 2023 (see Note 7 for further discussion) . The Company also has access to capital under ATM Common Stock Sales (defined below in Note 9), which had $ 6.2 million remaining available to sell under the ATM agreement as of March 31, 2023. The Company’s Loan and Security Agreement, dated March 22, 2023, or the CIBC Loan Agreement, with CIBC Bank USA, or CIBC, which matures on August 31, 2024 ($ 18.3 million outstanding as of March 31, 2023), and its debt facilities with National Australia Bank, or NAB, contain various operating and financial covenants (see Note 7 ). Adverse geopolitical and macroeconomic events and other factors affecting the Company’s results of operations have increased the risk of the Company’s inability to comply with these covenants, which could result in acceleration of its repayment obligations and foreclosure on its pledged assets. For example, the Company was not in compliance with certain covenants in the CIBC Loan Agreement as of June 30, 2021, December 31, 2021, March 31, 2022, June 15, 2022, and June 30, 2022, and was required to obtain waivers and/or amendments from CIBC. The CIBC Loan Agreement as presently in effect requires the Company to meet minimum Adjusted EBITDA levels on a quarterly basis, and the NAB Finance Agreement (as defined below) includes an undertaking that requires the Company to maintain a net related entity position of not more than USD $ 18.5 million. The Company met all financial covenants as of March 31, 202 3, but there can be no assurance the Company will be successful in meeting its covenants or securing future waivers and/or amendments from its lenders. If the Company is unsuccessful in doing so and cannot obtain other financing options, it may need to reduce the scope of its operations, repay amounts owed to its lenders or sell certain assets. These operating and liquidity factors raise substantial doubt regarding the Company’s ability to continue as a going concern. The Co mpany’s condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. International Operations The Company translates its foreign operations’ assets and liabilities denominated in foreign currencies into U.S. dollars at the current rates of exchange as of the balance sheet date and income and expense items at the average exchange rate for the reporting period. Translation adjustments resulting from exchange rate fluctuations are recorded in the cumulative translation account, a component of accumulated other comprehensive income (loss). Gains or losses from foreign currency transactions are included in the condensed consolidated statement of operations. For the nine months ended March 31, 2023, a $ 0.6 million loss was recognized to cost of revenues an d a $ 0.7 mi llion foreign currency loss was recorded to other (income) expense. For the three months ended March 31, 2023, a $ 0.4 million loss was recognized to cost of revenues an d a $ 0.3 mi llion foreign currency loss was recorded to other (income) expense. Accounts Receivable The Company provides an allowance for doubtful trade receivables equal to the estimated uncollectible amounts. That estimate is based on historical collection experience, current economic and market conditions and a review of the current status of each customer’s trade accounts receivable. The allowance for doubtful trade receivables was $ 258,821 and $ 233,927 on March 31, 2023 and June 30, 2022, respectively. Inventories Components of inventory are as follows: As of As of March 31, 2023 June 30, 2022 Raw materials and supplies $ 3,312,634 $ 2,645,764 Work in progress 12,890,422 6,677,980 Finished goods 39,463,571 45,192,150 Inventories, net $ 55,666,627 $ 54,515,894 Employee Retention Credit In response to the COVID-19 pandemic, the Employee Retention Credit, or ERC, was established under the Coronavirus Aid, Relief, and Economic Security Act. The ERC is a refundable tax credit meant for businesses that continued to pay employees while shut down due to the COVID-19 pandemic or had significant declines in gross receipts from March 13, 2020 to December 31, 2021. Companies who meet the eligibility requirements can claim the ERC on an original or adjusted employment tax return for a period within those dates. In March 2023, the Company determined that it qualifies for $ 1.4 million in relief for the period from April 1, 2021 to September 30, 2021. Upon receipt of the relief, the Company will owe $ 0.2 million in tax advisory costs associated with the assessment of the tax credit. Further research is ongoing to determine if the Company qualifies for any other reporting periods. As there is no authoritative guidance under US GAAP for government assistance to for-profit business entities, the Company accounts for the ERC by analogy to International Accounting Standards 20, or IAS 20, Accounting for Government Grants and Disclosure of Government Assistance . In accordance with IAS 20, management determined it has reasonable assurance of receipt of the identified ERC amount and recorded the $ 1.4 million benefit as Government grant income in the condensed consolidated statements of operations during the three and nine month periods ended March 31, 2023. A corresponding accrual of the tax credit receivable was recorded as a current asset on the condensed consolidated balance sheet as of March 31, 2023. Income Taxes Deferred tax assets and liabilities are determined based on differences between the financial statement and tax basis of assets and liabilities, as well as a consideration of net operating loss and credit carry forwards, using enacted tax rates in effect for the period in which the differences are expected to impact taxable income. A valuation allowance is established, when necessary, to reduce deferred tax assets to the amount that is more likely than not to be realized. The Company’s effective tax rate for the three and nine months ended March 31, 2023 and 2022 ha s been affected by the valuation allowance on the Company’s deferred tax assets as well as the gain related to the formation of our wheat partnership with Trigall. Net Income (Loss) Per Common Share Data The Company computes earnings per share using the two-class method. The two-class method requires an earnings allocation formula that determines earnings per share for common shareholders and participating security holders according to dividends declared and participating rights in undistributed earnings. The Company's Series B Preferred Stock and related warrant, or Series B Warrant (see Note 14 of the Notes to Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended June 30, 2022 , as filed with the SEC), are participating securities because holders of such shares have non-forfeitable dividend rights and participate in any undistributed earnings with common stock. Under the two-class method, total dividends provided to the holders of participating securities and undistributed earnings allocated to participating securities, are subtracted from net income attributable to the Company in determining net loss attributable to common shareholders in the two-class earnings per share, or EPS, calculation. Accretion to the redemption value for the Series B Preferred Stock is also treated as a deemed dividend and subtracted from net income attributable to shareholders. There were no undistributed earnings to allocate to the participating securities in the three and nine month periods ended March 31, 2023 and 2022. The calculation of net loss per common share is shown in the table below: Three Months Ended March 31, Nine Months Ended March 31, 2023 2022 2023 2022 Numerator: Net income (loss) attributable to S&W Seed Company $ 32,119,365 $ ( 7,304,923 ) $ 21,624,419 $ ( 23,500,000 ) Dividends accrued for participating securities ( 95,299 ) ( 40,276 ) ( 271,746 ) ( 40,276 ) Accretion of Series B Preferred Stock redemption value ( 25,838 ) ( 12,919 ) ( 77,514 ) ( 12,919 ) Numerator for net income (loss) per common share - basic and diluted $ 31,998,228 $ ( 7,358,118 ) $ 21,275,159 $ ( 23,553,195 ) Denominator: Denominator for basic EPS - weighted average shares 42,790,693 39,515,547 42,681,201 38,240,917 Less: weighted average shares - dilutive securities: Employee stock options 182,574 — 60,858 — Employee restricted stock options 192,881 — 131,771 — Denominator for diluted EPS - weighted average shares 43,166,148 39,515,547 42,873,830 38,240,917 Net income (loss) per common share - basic $ 0.75 $ ( 0.19 ) $ 0.50 $ ( 0.62 ) Net income (loss) per common share - diluted $ 0.74 $ ( 0.19 ) $ 0.50 $ ( 0.62 ) Anti-dilutive shares, which have been excluded from the computation of diluted income (loss) per share, included 4,319,232 employee stock options, 1,695,000 shares issuable upon conversion of the Series B Convertible Preferred Stock, warrants to purchase 2,633,400 shares of common stock related to the MFP Loan Agreement (as defined below) , 559,350 warrants issued with the Company's Series B Convertible Preferred Stock, and 48,439 restricted stock units. The terms and conditions of these securities are more fully described in Note 9 and Note 10 in these condensed consolidated financial statements and in Note 13 and Note 14 of the Notes to Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended June 30, 2022, as filed with the SEC. For the period ended March 31, 2022 , all potentially dilutive shares were anti-dilutive and excluded from the calculation of diluted loss per share because net losses were recognized. Concentrations No single customer accounted for more than 10 % of the Company's revenue for the three and nine months ended March 31, 2023 and 2022. No one customer accounted for more than 10 % of the Company’s accounts receivable as of March 31, 2023 and as of June 30, 2022. The Company sells a substantial portion of its products to international customers (see Note 4 ). Sales to international markets represented 55 % and 60 % of revenue during the three months ended March 31, 2023 and 2022 , respectively. Sales to international markets represented 75 % and 70 % of revenue during the nine months ended March 31, 2023 and 2022 , respectively. The net book value of fixed assets located outside the United States was 31 % and 22 % of total fixed assets on March 31, 2023 and June 30, 2022 , respectively. Cash balances located outside of the United States may not be insured and totaled $ 439,920 and $ 811,551 on March 31, 2023 and June 30, 2022 , respectively. Cash balances residing in the United States exceeding the Federal Deposit Insurance Corporation limit of $ 250,000 totaled $ 879,542 and $ 994,957 on March 31, 2023 and June 30, 2022 , respectively. Derivative Financial Instruments The Company’s subsidiary, S&W Australia, is exposed to foreign currency exchange rate fluctuations in the normal course of its business, which the Company at times manages through the use of foreign currency derivative financial instruments. The Company has entered into foreign currency forward contracts and foreign currency call options (see Note 8) and accounts for these instruments in accordance with ASC Topic 815, “Derivatives and Hedging,” which establishes accounting and reporting standards requiring that derivative instruments be recorded on the balance sheet as either an asset or liability measured at fair value. The Company’s foreign currency contracts and options are not designated as hedging instruments under ASC 815; accordingly, changes in the fair value are recorded in current period earnings. Premiums paid for foreign currency options with strike prices below the spot market price when acquired represent the time value of the option, as there is no intrinsic value. Such premiums are recorded as a current asset and amortized over the option term. Cu rrency options are measured at fair value if the market price at the reporting date exceeds the strike price. When the strike price exceeds the market price, no liability is recorded as the Company has no obligation to exercise the options. Fair Value of Financial Instruments The Company discloses assets and liabilities that are recognized and measured at fair value, presented in a three-tier fair value hierarchy, as follows: • Level 1. Observable inputs such as quoted prices in active markets; • Level 2. Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and • Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The carrying value of cash and cash equivalents, financial commitment assets (see Note 9), the promissory note issued from Trigall (see Note 11), accounts payable, short-term and all long-term borrowings, as reflected in the condensed consolidated balance sheets, approximate fair value because of the short-term maturity of these instruments or interest rates commensurate with market rates. There have been no changes in operations and/or credit characteristics since the date of issuance that could impact the relationship between interest rates and market rates. S&W received a $ 6.0 million note receivable due from Shell in connection with the Vision Bioenergy partnership transaction (see Note 11). The note, which is due in February 2024, was initially recorded at its $ 5.7 million present value discounted at a rate of 4.4 %, which is our estimated discount rate for similar instruments. The receivable balance is being accreted to the full receivable amount on a straight-line basis over the remaining receivable term due to its short-term maturity. The receivable balanc e was $ 5.8 million as of March 31, 2023. Also in conjunction with the Vision Bioenergy partnership transaction, S&W received a one-time option, or Purchase Option, exercisable at any time on or before the fifth anniversary of the closing of the partnership transaction, to repurchase a 6 % membership interest from Shell. The option repurchase prices range between approximately $ 7.1 and $ 12.0 million, depending on the date on which such purchase is completed. The Purchase Option was valued at $ 0.6 million using a lattice option valuation model. The valuation model incorporated significant, unobservable inputs including a discounted cash flow model based on management projections of future Vision Bioenergy results and an estimate of the current per share value of Vision Bioenergy shares. In the model, the estimate of the current per share value was discounted to account for lack of control and marketability, which were considered to be part of the unit of account given the restrictions of the limited liability company agreement that governs the ownership rights of the members. Other unobservable inputs included the risk-free rates and the estimated future stock volatility based on the historical stock price volatilities of other market participants. A full fair value analysis will be performed at each fiscal year-end or when there is an indication that there may be an impairment to the valuation. Management will estimate and adjust the balance for interim periods. No adjustment to the fair value was recorded as of March 31, 2023. Quantitative information about Level 3 fair value measurement is as follows: Fair Value at 3/31/23 Valuation Technique Unobservable Input Range Purchase Option $ 604,000 Option Model Risk-free rate 3.8 % - 4.9 % Stock price volatility 60 % - 65 % Lack of control premium 13 % Lack of marketability premium 30 % Assets and liabilities that are recognized and measured at fair value on a recurring basis are categorized as follows: Fair Value Measurements as of March 31, 2023 Using: Level 1 Level 2 Level 3 Foreign exchange contract liability $ — $ 812,362 $ — Vision Bioenergy interest purchase option — — 604,000 Total $ — $ 812,362 $ 604,000 Fair Value Measurements as of June 30, 2022 Using: Level 1 Level 2 Level 3 Foreign exchange contract liability $ — $ 996,106 $ — Total $ — $ 996,106 $ — Recent Accounting Pronouncements Not Yet Adopted We have evaluated all issued and unadopted Accounting Standards Updates and believe the adoption of these standards will not have a material impact on our condensed consolidated statements of operations, comprehensive income, balance sheets, or cash flows.

Leases

Leases	9 Months Ended
Leases	Mar. 31, 2023
Lessee Disclosure [Abstract]
LEASES	NOTE 3 - LEASES The Company leases office and laboratory space, research plots and equipment used in connection with its operations under various operating and finance leases. The components of lease assets and liabilities as of March 31, 2023 and June 30, 2022 are as follows: Leases Balance Sheet Classification: March 31, 2023 June 30, 2022 Assets: Right of use assets - finance leases $ 1,736,128 $ 2,071,609 Accumulated amortization - finance leases ( 1,104,261 ) ( 1,131,842 ) Right of use assets - finance leases, net Other assets 631,867 939,767 Right of use assets - operating leases Right of use assets - operating leases 3,344,109 4,094,253 Total lease assets $ 3,975,976 $ 5,034,020 Liabilities: Current lease liabilities - finance leases Current portion of long-term debt, net $ 402,164 $ 804,309 Current lease liabilities - operating leases Accrued expenses and other current liabilities 1,254,357 1,341,198 Long-term portion of lease liabilities - Long-term debt, net, less current portion 246,977 500,723 Long-term portion of lease liabilities - Other non-current liabilities 2,337,168 3,042,311 Total lease liabilities $ 4,240,666 $ 5,688,541 The components of lease cost are as follows: Lease cost: Income Statement Classification: Three Months Ended March 31, 2023 Nine Months Ended March 31, 2023 Operating lease cost Cost of revenue $ 193,011 $ 540,260 Operating lease cost Selling, general and administrative expenses 45,040 155,288 Operating lease cost Research and development expenses 92,016 316,833 Finance lease cost Depreciation and amortization 120,263 385,901 Finance lease cost Interest expense, net 8,714 30,033 Total lease costs $ 459,044 $ 1,428,315 Maturities of lease liabilities as of March 31, 2023, are as follows: Fiscal Year Operating Leases Finance Leases Remainder of 2023 $ 359,999 $ 126,830 2024 1,387,727 367,055 2025 978,126 144,272 2026 641,966 51,829 2027 400,807 - Thereafter 102,974 - Total lease payments 3,871,599 689,986 Less: Interest ( 280,074 ) ( 40,845 ) Present value of lease liabilities $ 3,591,525 $ 649,141 The following are the weighted average assumptions used for lease term and discount rate and supplemental cash flow information related to leases as of March 31, 2023: Operating lease remaining lease term 3.3 years Operating lease discount rate 4.14 % Finance lease remaining lease term 1.1 years Finance lease discount rate 6.04 % Cash paid for operating leases $ 1,063,242 Cash paid for finance leases 490,810

Revenue Recognition

Revenue Recognition	9 Months Ended
Revenue Recognition	Mar. 31, 2023
Revenues [Abstract]
REVENUE RECOGNITION	NOTE 4 - REVENUE RECOGNITION The Company derives its revenue primarily from the sale of seed products to seed distributors. From time to time, the Company utilizes excess capacity to provide conditioning, treating and packaging services to other seed producers. The Company also derives service revenue from its two partnerships, Trigall Australia and Vision Bioenergy, by providing administrative services under a service level agreement. Revenue from seed product sales is recognized at the point in time at which control of the product is transferred to the customer. Generally, this occurs upon shipment of the product. Pricing for such transactions is negotiated and determined at the time the contracts are signed. We have elected the practical expedient that allows us to account for shipping and handling activities as a fulfillment cost, and we accrue those costs when the related revenue is recognized. The Company has certain contracts with customers that offer a limited right of return on certain branded products through the end of the current sales year (September through August). The products must be in an unopened and undamaged state and must be resalable in the sole opinion of the Company to qualify for a refund. The Company uses a historical returns percentage to estimate the refund liability and records a reduction of revenue in the period in which revenue is recognized. Contract Assets and Liabilities Accounts receivable represent amounts that are payable to the Company by its customers subject only to the passage of time. Payment terms on invoices are generally 30 to 180 days for export customers and end of sales season (September 30 th ) for branded products sold within the United States. As the period between the transfer of goods and/or services to the customer and receipt of payment is less than one year , the Company does not separately account for a financing component in its contracts with customers. The Company provides an allowance for doubtful trade receivables equal to the estimated uncollectible amounts (see Note 2). When it becomes probable that a trade receivable will not be collected, it is written off against the allowance for doubtful accounts. If an account that has been written off is subsequently corrected, the provision for doubtful receivables is reversed, which can result in a net negative provision in a period. During the three and nine months ended March 31, 2023, the Company recorded a net provision for doubtful receivables of $ 48,634 and a net reversal of the allowance for d oubtful accounts of ($ 76,575 ), r espectively. Deferred revenue represents payments received from customers in advance of completion of the Company's performance obligation. During the nine months ended March 31, 2023, the Company recogn ized $ 0.6 million of revenue that was included in the deferred balance as of June 30, 2022. During the nine months ended March 31, 2022, the Company reco gnized $ 0.4 million of revenue that was included in the deferred balance as of June 30, 2021. ADAMA Collaboration Agreement The Company has a collaboration agreement, or Collaboration Agreement, with Makhteshim Agan of North America, Inc., or ADAMA, for the development and commercialization of the Double Team Sorghum Weed Control System, or DT, which is comprised of ADAMA’s ACCase herbicide used in concert with the Company’s ACCase tolerant ATS Sorghum product, Double Team TM Sorghum Cropping Solution. Both parties are active participants in the operating activities of the collaboration and exposed to significant risks and rewards depending on the commercial success of the activities. Although the DT product is designed to be used as a system, the Company sells only the Double Team TM Sorghum seed portion of the system and recognizes the revenue consistent with its sales of other seed products. Under the Collaboration Agreement, the Company will only label and promote ATS Sorghum products with ADAMA herbicides, while ADAMA will not sell ACCase herbicides for use on competing ATS Sorghum products. Further, all DT related trademarks are jointly owned by the Company and ADAMA, and each company grants the other a license free royalty to use these DT related trademarks. The parties have agreed to share the increase in commercial value created and realized by DT, or Total Value Share, with the Company and ADAMA taking 60 % and 40 % of the Total Share Value, respectively. The Total Share Value is the sum of (a) the increase in gross margin realized by the Company from sale of the Double Team TM Sorghum product compared to margins realized by its non-ATS Sorghum products, (b) 100 % of the ADAMA’s ACCase herbicide margin, and (c) any DT-related technology licensing fees received by either party. The Total Value Share is estimated each calendar quarter and a final net settlement is paid at the end of each market year, which ends in August. Estimated and final net settlement amounts to be paid or received are recorded as adjustments to cost of sales. Double Team TM Sorghum seed sale s were $ 3.8 million and $ 5.0 million for the three and nine months ended March 31, 2023 , respectively, and $ 1.7 milli on for the three and nine months ended March 31, 2022. The Total Value Share net settlement amounts pursuant to the Collaboration Agreement were not significant for the three and nine months ended March 31, 2023 and 2022. Disaggregation of Revenue The Company disaggregates revenue by type of contract and by destination country. The following table shows revenue from external sources by type of contract: Three Months Ended March 31, Nine Months Ended March 31, 2023 2022 2023 2022 Seed sales $ 17,382,360 $ 22,791,148 $ 50,054,978 $ 49,946,635 Services 279,947 395,729 410,996 1,403,332 Total revenue $ 17,662,307 $ 23,186,877 $ 50,465,974 $ 51,349,967 The following tables show revenue and percentage of revenue from external sources by destination country: Three Months Ended March 31, Nine Months Ended March 31, 2023 2022 2023 2022 United States $ 8,035,365 45 % $ 9,270,851 40 % $ 12,751,506 25 % $ 15,340,257 30 % Australia 7,336,338 42 % 8,846,660 38 % 12,522,642 25 % 14,526,512 28 % Saudi Arabia 292,150 2 % 1,168,502 5 % 7,631,494 15 % 6,316,258 12 % Mexico 482,300 3 % 602,060 3 % 4,297,823 8 % 2,833,622 6 % Libya — 0 % 929,335 4 % 2,995,608 6 % 1,668,044 3 % Sudan — 0 % 265,292 1 % 2,303,702 5 % 1,644,073 3 % Pakistan 240,935 1 % — 0 % 1,594,026 3 % 1,409,147 3 % South Africa ( 751 ) 0 % — 0 % 1,063,255 2 % 1,088,000 2 % Algeria 176,000 1 % 557,510 2 % 912,040 2 % 959,810 2 % Argentina ( 3,188 ) 0 % — 0 % 803,264 2 % 819,618 2 % Other 1,103,158 6 % 1,546,667 7 % 3,590,614 7 % 4,744,626 9 % Total revenue $ 17,662,307 100 % $ 23,186,877 100 % $ 50,465,974 100 % $ 51,349,967 100 %

Intangible Assets

Intangible Assets	9 Months Ended
Intangible Assets	Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	NOTE 5 – INTANGIBLE ASSETS Intangible assets consist of the following: Balance at Other Additions and Disposals Amortization Currency Translation Adjustment Balance at March 31, 2023 Trade name $ 1,084,791 $ — $ ( 147,630 ) $ ( 5,737 ) $ 931,424 Customer relationships 5,499,815 — ( 265,258 ) ( 131,244 ) 5,103,313 GI customer list 42,983 — ( 5,373 ) — 37,610 Supply agreement 775,241 — ( 56,725 ) — 718,516 Grower relationships 1,331,581 — ( 79,055 ) — 1,252,526 Intellectual property 23,035,925 — ( 1,039,162 ) — 21,996,763 License agreement 1,986,598 ( 1,885,907 ) ( 75,610 ) ( 25,081 ) ( 0 ) Internal use software 338,893 — ( 50,833 ) — 288,060 $ 34,095,827 $ ( 1,885,907 ) $ ( 1,719,646 ) $ ( 162,062 ) $ 30,328,212 Balance at Other Additions and Disposals Amortization Currency Translation Adjustment Balance at Trade name $ 1,310,489 $ — $ ( 203,009 ) $ ( 22,689 ) $ 1,084,791 Customer relationships 6,302,591 — ( 373,393 ) ( 429,383 ) 5,499,815 Non-compete 5,058 — ( 5,058 ) — — GI customer list 50,146 — ( 7,163 ) — 42,983 Supply agreement 850,874 — ( 75,633 ) — 775,241 Grower relationships 1,436,988 — ( 105,407 ) — 1,331,581 Intellectual property 24,427,857 — ( 1,391,932 ) — 23,035,925 License agreement 2,340,269 — ( 172,004 ) ( 181,667 ) 1,986,598 Internal use software 406,670 — ( 67,777 ) — 338,893 $ 37,130,942 $ — $ ( 2,401,376 ) $ ( 633,739 ) $ 34,095,827 On December 23, 2022, the Company transferred certain intellectual property rights under a license agreement to Trigall Australia as part of its equity investment in the partnership (see Note 11). Amorti zation expense totaled $ 548,438 and $ 598,399 for the three months ended March 31, 2023 and 2022, respectively. Amortization expense totaled $ 1,719,646 and $ 1,798,227 for the nine months ended March 31, 2023 and 2022, respectively. Estimated aggregate remaining amortization is as follows: 2023 2024 2025 2026 2027 Thereafter Amortization expense $ 527,879 $ 2,154,690 $ 2,114,725 $ 1,975,491 $ 1,924,607 $ 21,630,820

Property, Plant and Equipment

Property, Plant and Equipment	9 Months Ended
Property, Plant and Equipment	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT	NOTE 6 - PROPERTY, PLANT AND EQUIPMENT Components of property, plant and equipment were as follows: As of As of March 31, 2023 June 30, 2022 Land and improvements $ 942,919 $ 2,265,087 Buildings and improvements 3,371,017 8,119,960 Machinery and equipment 12,622,765 14,972,462 Vehicles 608,002 1,085,342 Leasehold improvements 552,810 552,810 Construction in progress 20,000 110,107 Total property, plant and equipment 18,117,513 27,105,768 Less: accumulated depreciation ( 7,875,828 ) ( 10,234,099 ) Property, plant and equipment, net $ 10,241,685 $ 16,871,669 Depreciation expense totaled $ 438,505 and $ 625,327 for the three months ended March 31, 2023 and 2022, respectively. Depreciation expense totaled $ 1,591,997 and $ 1,809,915 for the nine months ended March 31, 2023 and 2022 , respectively.

Debt

Debt	9 Months Ended
Debt	Mar. 31, 2023
Debt Disclosure [Abstract]
DEBT	NOTE 7 - DEBT Total debt outstanding is presented on the consolidated balance sheet as follows: March 31, 2023 June 30, 2022 Current portion of working capital lines of credit CIBC $ 18,279,289 $ 12,804,611 National Australia Bank Limited 24,771,500 338,314 Debt issuance costs ( 267,653 ) ( 464,028 ) Total current portion of working capital lines of credit, net 42,783,136 12,678,897 Long-term portion of working capital lines of credit, less current portion National Australia Bank Limited — 21,703,286 Total long-term portion of working capital lines of credit — 21,703,286 Total working capital lines of credit, net $ 42,783,136 $ 34,382,183 Current portion of long-term debt Finance leases $ 402,164 $ 804,309 Term Loan - National Australia Bank Limited 334,750 344,400 Machinery & equipment loans - National Australia Bank Limited 257,963 246,547 Machinery & equipment loans - Hyster 11,897 11,834 Vehicle loans - Ford Credit 51,277 40,341 Secured real estate note - Rooster — 6,905,995 Debt issuance costs — ( 36,643 ) Total current portion, net 1,058,051 8,316,783 Long-term debt, less current portion Finance leases 246,977 500,723 Term loan - National Australia Bank Limited 2,343,250 2,410,800 Machinery & equipment loans - National Australia Bank Limited 956,029 963,733 Machinery & equipment loans - Hyster 18,944 28,722 Vehicle loans - Ford Credit 83,532 88,583 Debt issuance costs — ( 21 ) Total long-term portion, net 3,648,732 3,992,540 Total debt, net $ 4,706,783 $ 12,309,323 CIBC Loan Agreement On December 26, 2019 , the Company entered into the CIBC Loan Agreement with CIBC, which originally provided for a $ 35.0 million credit facility, or the CIBC Credit Facility. As described in Note 8 to the Consolidated Financial Statements in the Company’s Annual Report on Form 10-K for the year ended June 30, 2022, the CIBC Loan Agreement was subsequently amended on several occasions through the year ended June 30, 2022. During the nine months ended March 31, 2023, the CIBC Loan Agreement was further amended as follows: • on September 22, 2022, the CIBC Loan Agreement was amended to, among other things, (i) specify that the borrowing base eligible inventory sublimit cannot be reduced below the proceeds available to be drawn under the MFP Letter of Credit (as defined below), (ii) waive the Company's non-compliance with certain financial covenants under the CIBC Loan Agreement and (iii) establish a minimum liquidity of no less than $ 1.0 million tested weekly as of the last day of each week for the remainder of the term of the CIBC Loan Agreement; • on October 28, 2022, the CIBC Loan Agreement was amended to, among other things, increase (i) the total revolving loan commitment to $ 21.0 million from $ 18.0 million and (ii) the borrowing base eligible inventory sublimit to $ 12.0 million from $ 9.0 million; • on December 23, 2022, the CIBC Loan Agreement was amended to, among other things, extend the maturity date of all revolving loans, advances and other obligations outstanding under the CIBC Loan Agreement from December 23, 2022 to March 23, 2023 ; and • on March 22, 2023, the Company entered into an Amended and Restated Loan and Security Agreement, or the Amended CIBC Loan Agreement, with CIBC, as administrative agent and sole lead arranger, and the other loan parties and lenders party thereto. The Amended CIBC Loan Agreement replaced the existing CIBC Loan Agreement. The Amended CIBC Loan Agreement now matures on August 31, 2024 . The Amended CIBC Loan Agreement provides for a senior secured credit facility, or the Amended CIBC Credit Facility, of up to $ 25.0 million from February 1 to October 31 of each year, and up to $ 18.0 million from November 1 to January 31 of each year. The proceeds of advances under the Amended CIBC Credit Facility may be used to finance the Company’s ongoing working capital requirements and other general corporate purposes. Availability of funds under the Amended CIBC Credit Facility is subject to a borrowing base equal to (a) up to 85 % of eligible domestic accounts receivable, plus (b) up to 90 % of eligible foreign accounts receivable, plus (c) up to the lesser of (i) 65 % of eligible inventory and (ii) 85 % of the appraised net orderly liquidation value of eligible inventory , in each case subject to an eligible inventory sublimit, in each case ((a), (b) and (c)), as more fully set forth in the Amended CIBC Loan Agreement and subject to lender reserves that CIBC may establish from time to time in its sole discretion, determined in good faith. Advances under the Amended CIBC Credit Facility bear interest at a rate per annum equal to a reference rate equal to CIBC’s prime rate at any time (or, if greater, the federal funds rate at such time plus 0.5 %) plus an applicable margin of 2.0 %. The interest rate was 10.0 % as of March 31, 2023. The Company’s obligations under the Amended CIBC Loan Agreement are secured by a first priority security interest in substantially all of the Company’s assets (subject to certain exceptions), including intellectual property. The Amended CIBC Loan Agreement contains certain customary representations and warranties, events of default, and affirmative and negative covenants, including limitations with respect to debt, liens, fundamental changes, asset sales, restricted payments, investments and transactions with affiliates, subject to certain exceptions. Amounts due under the Amended CIBC Loan Agreement may be accelerated upon an “event of default,” as defined in the Amended CIBC Loan Agreement, such as failure to pay amounts owed thereunder when due, breach of a covenant, material inaccuracy of a representation, or occurrence of bankruptcy or insolvency, subject in some cases to cure periods. Additionally, upon the occurrence and during the continuance of an event of default, CIBC may elect to increase the existing interest rate on all of the Company’s outstanding obligations by 2.0 % per annum. All amounts outstanding under the Amended CIBC Loan Agreement, including, but not limited to, accrued and unpaid principal and interest due under the CIBC Credit Facility, will be due and payable in full on August 31, 2024. The Company actively pursued multiple other lenders prior to entering into the Amended CIBC Loan Agreement on March 22, 2023. The financing charges incurred associated with these other lenders totaled $ 1.5 million and were written off to Other (income) expenses in the condensed consolidated statements of operations in March 2023. As of March 31, 2023, the Company was in compliance with all financial covenants contained in the CIBC Loan Agreement. As of March 31, 2023 , there was approximately $ 1.0 million of unused availability on the CIBC Credit Facility, which had an available borrowing base of $ 19.3 million. With additional collateral consisting of accounts receivable and inventories, the available borrowing base can increase by an additional $ 5.7 million, to a maximum amount of $ 25.0 million. Rooster Note During the nine months ended March 31, 2023, the Rooster Note (as defined in Note 8 to the Consolidated Financial Statements in the Company’s Annual Report on Form 10-K for the year ended June 30, 2022) was amended as follows: • on September 22, 2022, the Company entered into an amendment to extend the Rooster Note’s maturity date to December 23, 2022 ; and • on December 23, 2022, the Company entered into an amendment to the Rooster Note that (i) increased the interest rate on the Rooster Note from 7.75 % to 9.25 % per annum and (ii) extended the maturity date of the Rooster Note from December 23, 2022 to March 1, 2023 . On February 6, 2023, Shell paid off the approximately $ 6.6 million of outstanding principal and accrued interest on the Rooster Note in connection with the Vision Bioenergy partnership (see Note 11). Australian Facilities S&W Australia’s debt facilities with National Australia Bank, or NAB, as amended to date, or the NAB Finance Agreement, were amended and restated effective October 24, 2022 and further amended on October 25, 2022. Pursuant to the amendments contained in the NAB Finance Agreement, among other things: • the borrowing base line credit limit under S&W Australia’s seasonal credit facility was increased from AUD $ 32.0 million (USD $ 21.4 million as of March 31, 2023 ) to AUD $ 40.0 million (USD $ 26.8 million as of March 31, 2023 ), with a one-year maturity date extension to September 30, 2024 ; • the overdraft credit limit under S&W Australia’s seasonal credit facility was increased from AUD $ 1.0 million (USD $ 0.7 million as of March 31, 2023 ) to AUD $ 2.0 million (USD $ 1.3 million as of March 31, 2023 ), with a one-year maturity date extension to September 29, 2023 ; and • the maturity date of S&W Australia’s master asset finance facility was extended by one year to September 29, 2023 . After the amendments, the consolidated debt facilities under the NAB Finance Agreement provide for up to an aggregate of AUD $ 49.0 (USD $ 32.8 million as of March 31, 2023 ) of credit. The NAB Finance Agreement is guaranteed by S&W Seed Company up to a maximum of AUD $ 15.0 million (USD $ 10.0 million as of March 31, 2023). The October 2022 amendments to the NAB Finance Agreement contained an undertaking requiring the Company to maintain a net related entity position of not more than AUD $ 25.0 million, and the Company's ability to comply with this undertaking was subject to fluctuations in foreign currency conversion rates outside of the Company's control. Due to fluctuations in foreign currency conversion rates, the Company was not in compliance with this undertaking as of December 31, 2022 and the Company subsequently obtained a waiver from NAB with respect to such non-compliance. On February 8, 2023, the Company further amended the NAB Finance Agreement to change the required net related entity position from AUD $ 25.0 million to USD $ 18.5 million. The Company believes that this amendment will provide the Company with greater control over compliance with this undertaking. As of March 31, 2023, the Company was in compliance with all NAB Finance Agreement covenants. As of March 31, 2023 , approximately AUD $ 1.3 million (USD $ 0.8 millio n) re mained available for use under the NAB Finance Agreement, which had an available borrowing base of AUD $ 37.9 million (USD $ 25.4 million as of March 31, 2023 ). With additional collateral consisting of accounts receivable and inventories, the available borrowing base can increase by an additional AUD $ 4.1 million (USD $ 2.7 million as of March 31, 2023 ), to a maximum amount of AUD $ 42 million (USD $ 28.6 million as of March 31, 2023). MFP Loan Agreement On September 22, 2022, the Company’s largest stockholder, MFP Partners, L.P., or MFP, provided a letter of credit issued by JPMorgan Chase Bank, N.A. for the account of MFP, with an initial face amount of $ 9.0 million, or the MFP Letter of Credit, for the benefit of CIBC, as additional collateral to support the Company’s obligations under the CIBC Loan Agreement. The MFP Letter of Credit initially matured on January 23, 2023 , one month after the maturity date of the existing CIBC Loan Agreement. Concurrently, on September 22, 2022, the Company entered into a Subordinate Loan and Security Agreement, or the MFP Loan Agreement, with MFP, pursuant to which any draw CIBC may make on the MFP Letter of Credit will be deemed to be a term loan advance made by MFP to the Company. The MFP Loan Agreement initially provided for up to $ 9.0 million of term loan advances. Concurrent with the October 28, 2022, amendment to the CIBC Loan Agreement (as described above), MFP amended the MFP Letter of Credit to increase the face amount from $ 9.0 million to $ 12.0 million, and the MFP Loan Agreement was amended to increase the maximum amount of term loan advances available to the Company from $ 9.0 million to $ 12.0 million. In connection with the December 23, 2022, amendment to the CIBC Loan Agreement, MFP amended the MFP Letter of Credit, extending the maturity date from January 23, 2 023 to April 30, 2023 . In connection with the Company’s entry into the Amended CIBC Loan Agreement, MFP further amended letter of credit to increase the maximum amount of term loan advances to $ 13.0 million and extend the maturity date to September 30, 2024 . The MFP Loan Agreement will mature on November 30, 2025 . Pursuant to the MFP Loan Agreement, the Company will pay to MFP a cash fee through the maturity date of the MFP Letter of Credit equal to 3.50 % per annum on all amounts remaining undrawn under the MFP Letter of Credit. In the event any term advances are deemed made under the MFP Loan Agreement, such advances will bear interest at a rate per annum equal to term SOFR (with a floor of 1.25 %) plus 9.25 %, 50 % of which will be payable in cash on the last day of each fiscal quarter and 50 % of which will accrue as payment in kind interest payable on the maturity date, unless, with respect to any quarterly payment date, the Company elects to pay such interest in cash. Concurrent with the March 22, 2023 amendment to the CIBC Loan Agreement, the Company entered into a Third Amendment to Subordinate Loan and Security Agreement with MFP, or MFP Amendment, to (i) increase the aggregate amount of cash advances permitted from $ 12.0 million to $ 13.0 million; (ii) increase the cash fee payable to MFP on all amounts remaining undrawn under the Letter of Credit from 3.50 % to 4.25 % per annum; (iii) provide for the issuance of the MFP Warrant to MFP (see Note 9); and (iv) reflect the extension of the maturity date of the Letter of Credit to September 30, 2024 . The MFP Loan Agreement, as amended, includes customary affirmative and negative covenants and events of default, and is secured by substantially all of the Company’s assets and is subordinated to the CIBC Loan Agreement. Upon the occurrence and during the continuance of an event of default, MFP may declare all outstanding obligations under the MFP Loan Agreement immediately due and payable and take such other actions as set forth in the MFP Loan Agreement. Maturities of Long-Term Debt The annual maturities of long-term debt, excluding finance lease liabilities, are as follows: Fiscal Year Amount Remainder of 2023 $ 76,909 2024 668,649 2025 632,758 2026 2,330,226 2027 161,420 Thereafter 187,682 Total $ 4,057,644

Foreign Currency Forward Contra

Foreign Currency Forward Contracts and Options	9 Months Ended
Foreign Currency Forward Contracts and Options	Mar. 31, 2023
Foreign Currency [Abstract]
FOREIGN CURRENCY FORWARD CONTRACTS AND OPTIONS	NOTE 8 - FOREIGN CURRENCY FORWARD CONTRACTS AND OPTIONS The Company held foreign currency forward contracts with a notional value of $ 10,621,155 on March 31, 2023 , with maturities ranging from April 2023 to June 2023 . The Company records an asset or liability on the condensed consolidated balance sheet for the fair value of the foreign currency forward contracts. The foreign currency contract liabilities totaled $ 812,362 and $ 996,106 on March 31, 2023 and June 30, 2022, respectively. The Company recorded gains of $ 187,154 and $ 201,188 on foreign currency forward contracts for the three months ended March 31, 2023 and 2022 , respectively, and gain of $ 167,688 and loss of $ 50,971 for the nine months ended March 31, 2023 and 2022, respectively. Gains and losses on foreign exchange contracts are reflected in cost of revenue. In March 2023, the Company acquired foreign currency options with a total notional amount of $ 9.0 million. The strike prices on the transaction dates and as of March 31, 2023 were above the market price, so the options had no intrinsic value. Option premiums of $ 31,055 are reflected in the caption "Prepaid expenses and other current assets" on the condensed consolidated balance sheet as of March 31, 2023. The Company's accounting policies for foreign currency contracts and options are found in Note 2 under the section titled " Derivative Financial Instruments."

Equity

Equity	9 Months Ended
Equity	Mar. 31, 2023
Equity [Abstract]
EQUITY	NOTE 9 – EQUITY ATM Common Stock Sales On September 23, 2020, the Company entered into an At Market Issuance Sales Agreement, or the ATM Agreement, with B. Riley Securities, Inc., or B. Riley, under which it may offer and sell from time to time, at its sole discretion, shares of its common stock having an aggregate offering price of up to $ 17.1 million through B. Riley as its sales agent. On May 17, 2022, the Company amended the ATM Agreement to have an aggregate offering price of $ 24.6 million. For the three and nine months ended March 31, 2023, the Company received gross proceeds of approximately $ 0.2 million from the sale of 102,455 shares of its common stock pursuant to the A TM Agreement. For the three months ended March 31, 2022, the Company received gross proceeds of approximately $ 6.2 million for the sale of 2,633,052 shares of its common stock pursuant to the ATM agreement. For the nine months ended March 31, 2022, the Company received gross proceeds of approximately $ 6.2 million for the sale of 2,633,900 shares of its common stock pursuant to the ATM agreement. As of March 31, 2023, the Company had $ 6.2 million remaining available to sell under the ATM Agreement. MFP Warrants On September 22, 2022, the Company entered into a Subordinate Loan and Security Agreement, or the MFP Loan Agreement, with MFP, pursuant to which any draw CIBC may make on the MFP Letter of Credit will be deemed to be a term loan advance made by MFP to the Company (see Note 7 ). Pursuant to the terms and conditions of the MFP Loan agreement, on September 22, 2022, the Company issued to MFP a warrant, or Initial Warrant, to purchase up to 500,000 shares of the Company’s common stock, or Initial Warrant Shares, at $ 1.60 per share. The Initial Warrant expires five years from its issue date, or September 22, 2027. In connection with the October 28, 2022 and December 22, 2022 amendments to the MFP Letter of Credit, the Company issued to MFP additional warrants to purchase 166,700 and 666,700 shares of the Company’s common stock, respectively, at an exercise price of $ 1.60 per warrant share. The warrants will each expire five years from the date of issuance. In connection with the MFP Amendment, on March 22, 2023, the Company issued to MFP a warrant to purchase 1,300,000 shares of the Company’s common stock at an exercise price of $ 2.15 per MFP warrant share. The warrants will expire five years from the date of issuance. In total, warrants to purchase 2,633,400 shares of the Company’s common stock were issued to MFP in connection with the MFP Loan Agreement, or MFP Warrants, during the nine months ended March 31, 2023. The stated purchase prices of all of the MFP Warrants are subject to adjustment in connection with any stock dividends and splits, distributions with respect to common stock and certain fundamental transactions as described in the MFP Warrant. The MFP Warrants were valued using the Black-Scholes-Merton model as of the respective issue dates and recorded as financial commitment assets within the caption "Prepaid expenses and other current assets" on the condensed consolidated balance sheet. The MFP Warrants financial commitment assets are amortized on a straight-line basis over the period from their initial issue dates through the end of the related MFP Letter of Credit commitment periods. During the nine months ended March 31, 2023, an aggregate value of $ 1,894,901 related to the MFP Warrants was capitalized, of which $ 626,141 w as amortized as interest expense. MFP is the Company’s largest shareholder. One of the Company’s directors, Alexander C. Matina, is Vice President and Portfolio Manager of MFP Investors LLC, the general partner of MFP.

Equity-Based Compensation

Equity-Based Compensation	9 Months Ended
Equity-Based Compensation	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
EQUITY-BASED COMPENSATION	NOTE 10 - EQUITY-BASED COMPENSATION Stock Options During the nine months ended March 31, 2023 , the Company granted options to purchase 1,289,675 shares of its common stock to certain of its directors, members of the executive management team, other employees, and non-employee service providers at exercise prices ranging from $ 0.81 - $ 1.89 per share. These options vest in either quarterly or annual periods over one to three years and expire ten years from the date of grant. A summary of stock option activity for the nine months ended March 31, 2023 and the year ended June 30, 2022 is presented below: Number of Weighted - Weighted- Aggregate Outstanding at June 30, 2021 3,776,568 $ 2.65 8.0 $ 3,962,766 Granted 994,725 2.63 Exercised ( 38,774 ) 2.33 Canceled/forfeited/expired ( 95,419 ) 2.82 Outstanding at June 30, 2022 4,637,100 $ 2.64 6.6 $ — Granted 1,289,675 1.26 Exercised ( 1,050 ) 0.95 Canceled/forfeited/expired ( 844,545 ) 2.79 Outstanding at March 31, 2023 5,081,180 $ 2.27 7.2 $ 459,346 Options vested and exercisable at March 31, 2023 3,235,391 $ 2.59 6.1 $ 39,501 Options vested and expected to vest as of March 31, 2023 5,071,515 $ 2.27 7.2 $ 455,713 The weighted average grant date per share fair value of options granted during the three and nine months ended March 31, 2023 was $ 0.70 . On March 31, 2023 , the Company had $ 1,131,866 of unrecognized stock compensation expense, net of estimated forfeitures, related to the options under the S&W Seed Company 2009 Equity Incentive Plan and the S&W Seed Company 2019 Equity Incentive Plan, or 2019 Plan, which will be recognized over the weighted average remaining service period of 1.41 years. The Company settles employee stock option exercises with newly issued shares of common stock. Restricted Stock Units During the nine months ended March 31, 2023 , the Company issued 495,196 restricted stock units to its directors, certain members of the executive management team, other employees, and non-employee service providers. The restricted stock units have varying vesting periods ranging from immediate vesting to quarterly or annual installments over one to three-year s. The fair value of the awards granted during the nine months ended March 31, 2023 and 2022 totaled $ 563,446 and $ 829,780 , respectively, and was based on the closing stock price on the date of grants. A summary of activity related to non-vested restricted stock units is presented below: Number of Weighted-Average Weighted-Average Nonvested restricted units outstanding at June 30, 2021 361,570 $ 2.51 1.3 Granted 304,421 2.78 — Vested ( 391,036 ) 2.62 — Forfeited ( 7,036 ) 2.35 — Nonvested restricted units outstanding at June 30, 2022 267,919 $ 2.66 1.2 Granted 495,196 1.14 1.6 Vested ( 224,164 ) 2.55 — Forfeited ( 8,750 ) 2.50 — Nonvested restricted units outstanding at March 31, 2023 530,201 $ 1.29 1.7 On March 31, 2023 , the Company had $ 461,652 of unrecognized stock compensation expense related to the restricted stock units, which will be recognized over the weighted average remaining service period of 1.51 years. Stock-based Compensation Expense Stock-based compensation expense recorded for grants of stock options, restricted stock and restricted stock units for the three months ended March 31, 2023 and 2022 totaled $ 620,887 and $ 413,293 , respectively. Stock-based compensation expense recorded for grants of stock options, restricted stock and restricted stock units for the nine months ended March 31, 2023 and 2022, totaled $ 1,382,895 and $ 1,821,808 , respectively. On March 31, 2023 , there were 1,642,198 shares available under the 2019 Plan for future grants and awards. Weighted-average assumptions used in the Black-Scholes-Merton model are set forth below for the periods indicated: March 31, 2023 March 31, 2022 Risk free rate 2.9 % - 4.4 % 0.8 % - 1.1 % Dividend yield — — Volatility 64.7 % - 66.1 % 61.8 % - 63.8 % Average forfeiture assumptions 8.2 % 2.8 %

Investments

Investments	9 Months Ended
Investments	Mar. 31, 2023
Equity Method Investments and Joint Ventures [Abstract]
INVESTMENTS	NOte 11 - investments Shell Partnership On February 6, 2023, or Closing Date, the Company and Shell entered into a Contribution and Membership Interest Purchase Agreement, or Purchase Agreement, relating to a partnership for the development and production of sustainable biofuel feedstocks through its newly created subsidiary Vision Bioenergy Oilseeds LLC, or Vision Bioenergy, pursuant to which: • The Company (i) contributed its Nampa, Idaho production and research facilities, or the Nampa Facilities, to Vision Bioenergy, along with certain personal property, including vehicles, fixed assets and other similar equipment; (ii) caused Vision Bioenergy to make offers of employment to certain key personnel; (iii) assigned to Vision Bioenergy certain contracts and permits; and (iv) agreed to a two-year non-solicitation covenant with respect to the personnel transferred to Vision Bioenergy. • On the Closing Date, Shell (i) made a $ 13.2 million cash contribution to Vision Bioenergy; (ii) paid $ 7.0 million to the Company; and (iii) paid $ 6.8 million to retire in full the principal, accrued interest and related settlement costs of the Rooster Note, which was secured by a priority security interest in the property, plant and fixtures located at the Nampa Facilities. • In February 2024, Shell will be required to pay an additional $ 6.0 million to the Company, subject to adjustment in certain circumstances. The Purchase Agreement provides that this required payment could be decreased by up to $ 4.5 million if (i) the effective employment date of the certain key personnel transferred to Vision Bioenergy, or Transferred Personnel, is later than May 7, 2023, or any of the Transferred Personnel are no longer employed by Vision Bioenergy after February 6, 2024 and (ii) the Company or Vision Bioenergy, as applicable, fail to replace such Transferred Personnel with personnel of reasonably similar qualifications within 90 days of the events covered in clause (i) above. The Company’s management deemed that the full $ 6.0 million payment from Shell to the Company was realizable due to the high likelihood that the key employees would remain employed for the first year, or in any event could be replaced within 90 days. The fair value of the full amount of this payment, based on the discounted value of the payment as of the Closing Date, was $ 5.7 million, which was recorded on the condensed consolidated balance sheets in the caption Prepaid expenses and other current assets. • In February 2024, Shell will be required to make an additional $ 12.0 million cash contribution to Vision Bioenergy. The fair value of these February 2024 payments on the Closing Date, based on the face value of the payments discounted at Shell’s (incremental borrowing rate) was $ 11.5 million. • S&W received a one-time option, or Purchase Option, exercisable at any time on or before the fifth anniversary of the closing of the partnership tran saction, to purchase a 6 % membership interest from Shell for a purchase price ranging between approximately $ 7.1 and $ 12.0 million, depending on the date on which such purchase is completed. The fair market value of the Purchase Option on the Closing Date was $ 0.6 million based on a third party appraisal. • Upon the achievement of certain specified milestones, measured as of the fourth and seventh anniversaries of the closing of the partnership transaction, the Company is eligible to receive transfers of up to an additional aggregate 10 % interest in Vision Bioenergy from Shell, or Contingent Transfers. The basis for recognition and measurement of contingent consideration in deconsolidation is not addressed in ASC 810. The Company has made an accounting policy election to account for these contingent consideration items like property and casualty losses in accordance with ASC 610-30, in which anticipated insurance recoveries are limited to the lesser of (1) the amount of proceeds for which the likelihood of receipt is probable or (2) the total loss recognized. Under this approach, if the consideration received in the deconsolidation, excluding the contingent consideration, is greater than the carrying amount of the deconsolidated net assets, no contingent consideration would be recognized initially. Since the consideration received by the Company in sale of the interest in Vision Bioenergy to Shell was greater than the carrying value of the assets deconsolidated, no contingent consideration was recorded by the Company. Subsequent recognition and measurement of the contingent consideration would be based on the gain contingency model under ASC 450-30. Although no contingent assets were recorded by the Company, the Contingent Transfers were a material part of the Purchase Agreement negotiated by the parties and therefore were included in the valuation of Shell’s investment of Vision Bioenergy. The fair value of the Contingent Transfers was determined to be $ 1.1 million based on Monte Carlo analysis of management projections of free cash flows. The aggregate total value of the Shell’s payments to the Company and cash contributions to Vision Bioenergy on the Closing Date, the present value of Shell’s future cash payments and contributions, and the fair market values of the Purchase Option and Contingent Transfers, was $ 45.9 million. For this investment, Shell received a 66 % interest in Vision Bioenergy, while the Company retained a 34 % interest. Prior to the closing of the Purchase Agreement, the Vision Bioenergy subsidiary of the Company held production and other property, rights to certain proprietary seed varieties and other trade secrets, and an experienced workforce with the necessary skills, knowledge, or experience to perform a process on the inputs that could generate an output, that meet the definition of a business as defined by ASC 805-10. Accordingly, the transfer of the 66 % interest in Vision Bioenergy to Shell was accounted for as a sale of a business under ASC 805. Concurrent with the sale of the 66 % interest, Vision Bioenergy was deconsolidated from the Company’s books, and the retained interest was recorded as an investment. Shell’s $ 45.9 million investment for a 66 % interest reflected a total valuation of the Vision Bioenergy business of $ 69.6 million. The consideration received by the Company for Shell’s 66 % interest in Vision Bioenergy comprises the $ 7.0 million paid to the Company at closing, the retirement of $ 6.8 million of Company debt, the $ 5.7 million present value of the future payment to the Company described above, the $ 0.6 million fair market value of the Purchase Option, and the $ 23.7 million value of the equity investment, or $ 43.8 million in total. The total consideration, less the $ 5.5 million carrying value of the Nampa facility assets and inventory contributed by the Company to Vision Bioenergy, resulted in gain on the sale in the amount of $ 38.3 million. The gain is reported within the caption “Gain on equity method investments” on the condensed consolidated statements of operations. This consideration is summarized below: Equity investment $ 23,664,195 Cash 7,000,000 Debt retirement 6,840,879 Present value of future payment 5,747,126 Fixed assets and inventory transfer ( 5,532,694 ) Fair value of 6 % member purchase option 604,000 Gain on equity method investments $ 38,323,506 Vision Bioenergy’s five-member Board of Directors includes two directors designated by the Company. Through its Board representation and 34 % of the voting rights, the Company has significant influence in the management of Vision Bioenergy. Accordingly, the Company’s investment is accounted for using the equity method and reported within the “Equity method investments” caption on the condensed consolidated balance sheet. The Company recognizes its proportionate share of the reported earnings or losses of Vision Bioenergy through net income and as an adjustment to the investment balance. This proportionate share is subject to adjustments, such as for the elimination of intra-entity (intercompany) gains or losses or amortization of basis differences. Vision Bioenergy is a pass-through entity for income tax purposes, with income or loss distributed to the partners. The fair market values of the assets contributed to Vision Bioenergy by the Company at the Closing Date were determined by third-party market appraisals. The Nampa Facilities and other property with an aggregate carrying amount of $ 5.5 million were valued at $ 12.9 million. Rights established under a product uptake agreement with Shell and rights to certain proprietary seed technology with no carrying value on the Company's books, were valued at $ 18.1 million. These intangible assets were recorded on Vision Bioenergy's opening balance sheet and will be amortized through the end of their useful life. The total gain on the sale of the Vision Bioenergy interest recognized by the Company included $ 8.6 million related to the remeasurement of the retained investment in Vision Bioenergy to its fair value. The fair market values of the Nampa Facilities and other property and the Purchase Option are provisional pending receipt of the final valuations for those assets. On the Closing Date, the Company's proportionate 34 % share o f Vision Bioenergy’s equity was $ 23.7 million, calculated from the total valuation of the Vision Bioenergy business of $ 69.6 million. Of this, the Company’s equity share of Vision Bioenergy’s net identifiable assets was $ 18.9 million. The $ 4.8 million difference between the carrying amount of the equity method investment and the Company’s share of the net identifiable assets represented equity method goodwill. The equity method goodwill will not be subject to amortization but will assessed at least annually, or when certain triggering events occur, for impairment using fair value measurement techniques. The summarized unaudited balance sheet presented below reflects the financial information of Vision Bioenergy as of March 31, 2023: As of March 31, 2023 Cash $ 11,042,929 Other current assets 432,992 Fixed assets 14,385,791 Intangible assets 17,820,005 Goodwill 14,006,268 Other assets 165,796 TOTAL ASSETS $ 57,853,781 Current liabilities 581,549 Long-term liabilities 117,492 Equity 57,154,740 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 57,853,781 The summarized unaudited income statement presented below reflects the financial information of Vision Bioenergy for the three and nine months ended March 31, 2023: Three and Nine Months Ended March 31, 2023 Revenue $ 83,505 Gross profit (loss) ( 206,985 ) Loss from operations ( 953,718 ) Net loss ( 951,582 ) Trigall Australia Partnership Effective December 23, 2022, the Company’s wholly owned subsidiary, S&W Seed Company Australia Pty Ltd, or S&W Australia, entered into a partnership with Trigall Genetics S.A., or Trigall, for the development and marketing of wheat varieties in Australia. Under the terms of the partnership agreement, S&W Australia transferred certain intellectual property license rights and equipment into a wholly owned subsidiary and subsequently sold an 80 % interest in the subsidiary to Trigall. The subsidiary was renamed Trigall Australia Pty Ltd, or Trigall Australia. In return, S&W Australia received $ 2.0 million in cash, a $ 1.0 million promissory note to be paid in December 2023, and retained a 20 % ownership interest in Trigall Australia. The $ 1.0 million promissory note is reported within the "Prepaid expenses and other current assets" caption on the condensed consolidated balance sheet. The grossed-up $ 3.0 million investment by Trigall for an 80 % interest in Trigall Australia implied a $ 3.8 million valuation. S&W Australia’s 20 % retained interest, valued accordingly at $ 0.8 million, as of the transaction date, is reported within the “Equity method investments” caption on the condensed consolidated balance sheet. Management determined that the assets transferred to Trigall Australia did not meet the definition of a business for accounting purposes, and the sale was accounted for as an asset sale. The $ 3.8 million valuation, less the $ 2.0 million carrying value of assets contributed, resulted in a $ 1.8 million gain on the sale. The gain is reported within the caption “Gain on equity method investment” on the condensed consolidated statement of operations. The Company recognizes its proportionate share of the reported earnings or losses of Trigall, net of tax, through net income and as an adjustment to the investment balance. S&W Australia is obligated to make an aggregate of $ 0.6 million in capital contributions to Trigall Australia through June 2025, and has agreed to provide certain marketing, collection and other operational services in support of the partnership. Bioceres Investment As of June 30, 2021, the Company held an investment in Bioceres, S.A., a provider of crop productivity solutions headquartered in Argentina. During the third quarter of fiscal year 2022, the Company sold 71.4 % of the investment in Bioceres, S.A. for net proceeds of $ 1.0 million, which included a gain on the sale of marketable securities of $ 0.1 million. The carrying value of the remainder of the investment was $ 0.4 million at June 30, 2022, which was reported in Equity method investments on the Company's consolidated balance sheet. During the nine months ended March 31, 2023, the Company sold off the remainder of its investment in Bioceres, S.A. for net proceeds of $ 0.4 million, which included a gain on the sale of equity investment of $ 32,030 . The following summarizes the carrying amount of the Company's equity method investments reflected in the consolidated balance sheet: March 31, 2023 June 30, 2022 Carrying Amount Economic Interest Carrying Amount Economic Interest Vision Bioenergy $ 23,340,657 34 % $ — 0 % Trigall Australia 781,114 20 % — 0 % Bioceres — 0 % 367,970 1 % Total equity method investments $ 24,121,771 $ 367,970

Series B Convertible Preferred

Series B Convertible Preferred Stock	9 Months Ended
Series B Convertible Preferred Stock	Mar. 31, 2023
Temporary Equity Disclosure [Abstract]
Series B Convertible Preferred Stock	NOTE 12 – SERIES B CONVERTIBLE PREFERRED STOCK The terms and conditions of the Company’s Series B Convertible Preferred Stock and accompanying Warrant are presented in Note 14 to the Consolidated Financial Statements in the Company’s Annual Report on Form 10-K for the year ended June 30, 2022 . No issuances or conversions of Series B Convertible Preferred Stock occurred during the nine months ended March 31, 2023. Activity in the period consisted of accrual of dividends and accretion of the discount on the Warrants. The following summarizes changes to the Series B Convertible Preferred Stock: Balance at June 30, 2021 $ — Issuance of preferred stock 4,638,521 Dividends accrued 127,541 Accretion of discount for warrants 38,757 Balance at June 30, 2022 $ 4,804,819 Dividends accrued 271,746 Accretion of discount for warrants 77,514 Balance at March 31, 2023 $ 5,154,079

Non-Cash Activities for Stateme

Non-Cash Activities for Statements of Cash Flows	9 Months Ended
Non-Cash Activities for Statements of Cash Flows	Mar. 31, 2023
Supplemental Cash Flow Elements [Abstract]
NON-CASH ACTIVITIES FOR STATEMENTS OF CASH FLOWS	NO TE 13 - NON-CASH ACTIVITIES FOR STATEMENTS OF CASH FLOWS The below table represents supplemental information to the Company’s condensed consolidated statements of cash flows for non-cash activities during the nine months ended March 31, 2023 and 2022, respectively. Nine Months Ended March 31, 2023 2022 Non-cash investing activities: ROU assets financed by lease liabilities $ 498,143 $ 271,524 Consideration received from Shell for equity interest in Vision Bioenergy: Settlement of long-term debt principal, interest and other related costs 6,840,879 — Note receivable 5,747,127 — Membership purchase option 604,000 — Contribution of property, plant and equipment and inventory to Vision Bioenergy for equity interest ( 5,532,694 ) — Contribution of intangible assets to Trigall in exchange for equity investment and promissory note ( 1,750,000 ) — Non-cash financing activities: Warrants issued for financial commitment asset 1,894,901 — Dividends accrued for participating securities 271,746 40,276 Accretion of discount for Series B preferred stock warrants 77,514 12,919

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
Summary of Significant Accounting Policies (Policies)	Mar. 31, 2023
Accounting Policies [Abstract]
Investments and Partnership Activity	Investments and Partnership Activity Shell Partnership On February 6, 2023, S&W and Equilon Enterprises LLC (dba Shell Oil Products US, or Shell), entered into a partnership for the development and production of sustainable biofuel feedstocks through Vision Bioenergy Oilseeds LLC, or Vision Bioenergy. Under the terms of the partnership agreement, S&W contributed production and research facilities, along with certain personal property, including vehicles and other similar equipment, into its Vision Bioenergy subsidiary and subsequently sold a 66 % interest in the subsidiary to Shell. See Note 11 for further information. Trigall Australia Partnership Effective December 23, 2022, the Company’s wholly owned subsidiary, S&W Seed Company Australia Pty Ltd, or S&W Australia, entered into a partnership with Trigall Genetics S.A., or Trigall, for the development and marketing of wheat varieties in Australia. Under the terms of the partnership agreement, S&W Australia transferred certain intellectual property license rights and equipment into a wholly owned subsidiary and subsequently sold an 80 % interest in the subsidiary to Trigall. The subsidiary was renamed Trigall Australia Pty Ltd, or Trigall Australia. See Note 11 for further information. Bioceres Investment As of June 30, 2021, the Company held an investment in Bioceres, S.A., a provider of crop productivity solutions headquartered in Argentina. During the third quarter of fiscal year 2022, the Company sold 71.4 % of the investment in Bioceres, S.A. for net proceeds of $ 988,504 , which included a gain on the sale of marketable securities of $ 68,967 . The carrying value of the remainder of the investment was $ 367,970 at June 30, 2022, which was reported in Equity method investments on the Company's consolidated balance sheet. During the nine months ended March 31, 2023, the Company sold off the remainder of its investment in Bioceres, S.A. for net proceeds of $ 400,000 , which included a gain on the sale of equity investment of $ 32,030 .
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Estimates are adjusted to reflect actual experience when necessary. Significant estimates and assumptions affect many items in the financial statements. These include allowance for doubtful trade receivables, inventory valuation, the carrying value of the Company's equity investments, asset impairments, provisions for income taxes, grower accruals (an estimate of amounts payable to farmers who grow seed for the Company), contingencies and litigation. Significant estimates and assumptions are also used to establish the fair value and useful lives of depreciable tangible and certain intangible assets as well as valuing stock-based compensation. Actual results may differ from those estimates and assumptions, and such results may affect income, financial position or cash flows. The Company believes the estimates and assumptions underlying the accompanying condensed consolidated financial statements are reasonable and supportable based on the information available at the time the financial statements were prepared. However, certain adverse geopolitical and macroeconomic events, such as the ongoing conflict between Ukraine and Russia and related sanctions, and uncertain market conditions, including higher inflation and supply chain disruptions, have, among other things, negatively impacted the global economy, created significant volatility and disruption of financial markets, and significantly increased economic and demand uncertainty. These factors make many of the estimates and assumptions reflected in these condensed consolidated financial statements inherently less certain. Therefore, actual results may ultimately differ from those estimates to a greater degree than historically.
Liquidity and Going Concern	Liquidity and Going Concern Excluding the gain recognized in relation to the Vision Bioenergy partnership, the Company is not profitable and has recorded negative cash flows for the last several years. For the nine months ended March 31, 2023 , the Company reported net income of $ 21.6 million and net cash used in operations of $ 15.8 million. As of March 31, 2023 , the Company had cash on hand of $ 1.6 million. The Company had $ 1.8 million of unused availability from its working capital facilities as of March 31, 2023 (see Note 7 for further discussion) . The Company also has access to capital under ATM Common Stock Sales (defined below in Note 9), which had $ 6.2 million remaining available to sell under the ATM agreement as of March 31, 2023. The Company’s Loan and Security Agreement, dated March 22, 2023, or the CIBC Loan Agreement, with CIBC Bank USA, or CIBC, which matures on August 31, 2024 ($ 18.3 million outstanding as of March 31, 2023), and its debt facilities with National Australia Bank, or NAB, contain various operating and financial covenants (see Note 7 ). Adverse geopolitical and macroeconomic events and other factors affecting the Company’s results of operations have increased the risk of the Company’s inability to comply with these covenants, which could result in acceleration of its repayment obligations and foreclosure on its pledged assets. For example, the Company was not in compliance with certain covenants in the CIBC Loan Agreement as of June 30, 2021, December 31, 2021, March 31, 2022, June 15, 2022, and June 30, 2022, and was required to obtain waivers and/or amendments from CIBC. The CIBC Loan Agreement as presently in effect requires the Company to meet minimum Adjusted EBITDA levels on a quarterly basis, and the NAB Finance Agreement (as defined below) includes an undertaking that requires the Company to maintain a net related entity position of not more than USD $ 18.5 million. The Company met all financial covenants as of March 31, 202 3, but there can be no assurance the Company will be successful in meeting its covenants or securing future waivers and/or amendments from its lenders. If the Company is unsuccessful in doing so and cannot obtain other financing options, it may need to reduce the scope of its operations, repay amounts owed to its lenders or sell certain assets. These operating and liquidity factors raise substantial doubt regarding the Company’s ability to continue as a going concern. The Co mpany’s condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
International Operations	International Operations The Company translates its foreign operations’ assets and liabilities denominated in foreign currencies into U.S. dollars at the current rates of exchange as of the balance sheet date and income and expense items at the average exchange rate for the reporting period. Translation adjustments resulting from exchange rate fluctuations are recorded in the cumulative translation account, a component of accumulated other comprehensive income (loss). Gains or losses from foreign currency transactions are included in the condensed consolidated statement of operations. For the nine months ended March 31, 2023, a $ 0.6 million loss was recognized to cost of revenues an d a $ 0.7 mi llion foreign currency loss was recorded to other (income) expense. For the three months ended March 31, 2023, a $ 0.4 million loss was recognized to cost of revenues an d a $ 0.3 mi llion foreign currency loss was recorded to other (income) expense.
Accounts Receivable	Accounts Receivable The Company provides an allowance for doubtful trade receivables equal to the estimated uncollectible amounts. That estimate is based on historical collection experience, current economic and market conditions and a review of the current status of each customer’s trade accounts receivable. The allowance for doubtful trade receivables was $ 258,821 and $ 233,927 on March 31, 2023 and June 30, 2022, respectively.
Inventories	Inventories Components of inventory are as follows: As of As of March 31, 2023 June 30, 2022 Raw materials and supplies $ 3,312,634 $ 2,645,764 Work in progress 12,890,422 6,677,980 Finished goods 39,463,571 45,192,150 Inventories, net $ 55,666,627 $ 54,515,894
Employee Retention Credit	Employee Retention Credit In response to the COVID-19 pandemic, the Employee Retention Credit, or ERC, was established under the Coronavirus Aid, Relief, and Economic Security Act. The ERC is a refundable tax credit meant for businesses that continued to pay employees while shut down due to the COVID-19 pandemic or had significant declines in gross receipts from March 13, 2020 to December 31, 2021. Companies who meet the eligibility requirements can claim the ERC on an original or adjusted employment tax return for a period within those dates. In March 2023, the Company determined that it qualifies for $ 1.4 million in relief for the period from April 1, 2021 to September 30, 2021. Upon receipt of the relief, the Company will owe $ 0.2 million in tax advisory costs associated with the assessment of the tax credit. Further research is ongoing to determine if the Company qualifies for any other reporting periods. As there is no authoritative guidance under US GAAP for government assistance to for-profit business entities, the Company accounts for the ERC by analogy to International Accounting Standards 20, or IAS 20, Accounting for Government Grants and Disclosure of Government Assistance . In accordance with IAS 20, management determined it has reasonable assurance of receipt of the identified ERC amount and recorded the $ 1.4 million benefit as Government grant income in the condensed consolidated statements of operations during the three and nine month periods ended March 31, 2023. A corresponding accrual of the tax credit receivable was recorded as a current asset on the condensed consolidated balance sheet as of March 31, 2023.
Income Taxes	Income Taxes Deferred tax assets and liabilities are determined based on differences between the financial statement and tax basis of assets and liabilities, as well as a consideration of net operating loss and credit carry forwards, using enacted tax rates in effect for the period in which the differences are expected to impact taxable income. A valuation allowance is established, when necessary, to reduce deferred tax assets to the amount that is more likely than not to be realized. The Company’s effective tax rate for the three and nine months ended March 31, 2023 and 2022 ha s been affected by the valuation allowance on the Company’s deferred tax assets as well as the gain related to the formation of our wheat partnership with Trigall.
Net Income (Loss) Per Common Share Data	Net Income (Loss) Per Common Share Data The Company computes earnings per share using the two-class method. The two-class method requires an earnings allocation formula that determines earnings per share for common shareholders and participating security holders according to dividends declared and participating rights in undistributed earnings. The Company's Series B Preferred Stock and related warrant, or Series B Warrant (see Note 14 of the Notes to Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended June 30, 2022 , as filed with the SEC), are participating securities because holders of such shares have non-forfeitable dividend rights and participate in any undistributed earnings with common stock. Under the two-class method, total dividends provided to the holders of participating securities and undistributed earnings allocated to participating securities, are subtracted from net income attributable to the Company in determining net loss attributable to common shareholders in the two-class earnings per share, or EPS, calculation. Accretion to the redemption value for the Series B Preferred Stock is also treated as a deemed dividend and subtracted from net income attributable to shareholders. There were no undistributed earnings to allocate to the participating securities in the three and nine month periods ended March 31, 2023 and 2022. The calculation of net loss per common share is shown in the table below: Three Months Ended March 31, Nine Months Ended March 31, 2023 2022 2023 2022 Numerator: Net income (loss) attributable to S&W Seed Company $ 32,119,365 $ ( 7,304,923 ) $ 21,624,419 $ ( 23,500,000 ) Dividends accrued for participating securities ( 95,299 ) ( 40,276 ) ( 271,746 ) ( 40,276 ) Accretion of Series B Preferred Stock redemption value ( 25,838 ) ( 12,919 ) ( 77,514 ) ( 12,919 ) Numerator for net income (loss) per common share - basic and diluted $ 31,998,228 $ ( 7,358,118 ) $ 21,275,159 $ ( 23,553,195 ) Denominator: Denominator for basic EPS - weighted average shares 42,790,693 39,515,547 42,681,201 38,240,917 Less: weighted average shares - dilutive securities: Employee stock options 182,574 — 60,858 — Employee restricted stock options 192,881 — 131,771 — Denominator for diluted EPS - weighted average shares 43,166,148 39,515,547 42,873,830 38,240,917 Net income (loss) per common share - basic $ 0.75 $ ( 0.19 ) $ 0.50 $ ( 0.62 ) Net income (loss) per common share - diluted $ 0.74 $ ( 0.19 ) $ 0.50 $ ( 0.62 ) Anti-dilutive shares, which have been excluded from the computation of diluted income (loss) per share, included 4,319,232 employee stock options, 1,695,000 shares issuable upon conversion of the Series B Convertible Preferred Stock, warrants to purchase 2,633,400 shares of common stock related to the MFP Loan Agreement (as defined below) , 559,350 warrants issued with the Company's Series B Convertible Preferred Stock, and 48,439 restricted stock units. The terms and conditions of these securities are more fully described in Note 9 and Note 10 in these condensed consolidated financial statements and in Note 13 and Note 14 of the Notes to Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended June 30, 2022, as filed with the SEC. For the period ended March 31, 2022 , all potentially dilutive shares were anti-dilutive and excluded from the calculation of diluted loss per share because net losses were recognized.
Concentrations	Concentrations No single customer accounted for more than 10 % of the Company's revenue for the three and nine months ended March 31, 2023 and 2022. No one customer accounted for more than 10 % of the Company’s accounts receivable as of March 31, 2023 and as of June 30, 2022. The Company sells a substantial portion of its products to international customers (see Note 4 ). Sales to international markets represented 55 % and 60 % of revenue during the three months ended March 31, 2023 and 2022 , respectively. Sales to international markets represented 75 % and 70 % of revenue during the nine months ended March 31, 2023 and 2022 , respectively. The net book value of fixed assets located outside the United States was 31 % and 22 % of total fixed assets on March 31, 2023 and June 30, 2022 , respectively. Cash balances located outside of the United States may not be insured and totaled $ 439,920 and $ 811,551 on March 31, 2023 and June 30, 2022 , respectively. Cash balances residing in the United States exceeding the Federal Deposit Insurance Corporation limit of $ 250,000 totaled $ 879,542 and $ 994,957 on March 31, 2023 and June 30, 2022 , respectively.
Derivative Financial Instruments	Derivative Financial Instruments The Company’s subsidiary, S&W Australia, is exposed to foreign currency exchange rate fluctuations in the normal course of its business, which the Company at times manages through the use of foreign currency derivative financial instruments. The Company has entered into foreign currency forward contracts and foreign currency call options (see Note 8) and accounts for these instruments in accordance with ASC Topic 815, “Derivatives and Hedging,” which establishes accounting and reporting standards requiring that derivative instruments be recorded on the balance sheet as either an asset or liability measured at fair value. The Company’s foreign currency contracts and options are not designated as hedging instruments under ASC 815; accordingly, changes in the fair value are recorded in current period earnings. Premiums paid for foreign currency options with strike prices below the spot market price when acquired represent the time value of the option, as there is no intrinsic value. Such premiums are recorded as a current asset and amortized over the option term. Cu rrency options are measured at fair value if the market price at the reporting date exceeds the strike price. When the strike price exceeds the market price, no liability is recorded as the Company has no obligation to exercise the options.
Fair Values of Financial Instruments	Fair Value of Financial Instruments The Company discloses assets and liabilities that are recognized and measured at fair value, presented in a three-tier fair value hierarchy, as follows: • Level 1. Observable inputs such as quoted prices in active markets; • Level 2. Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and • Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The carrying value of cash and cash equivalents, financial commitment assets (see Note 9), the promissory note issued from Trigall (see Note 11), accounts payable, short-term and all long-term borrowings, as reflected in the condensed consolidated balance sheets, approximate fair value because of the short-term maturity of these instruments or interest rates commensurate with market rates. There have been no changes in operations and/or credit characteristics since the date of issuance that could impact the relationship between interest rates and market rates. S&W received a $ 6.0 million note receivable due from Shell in connection with the Vision Bioenergy partnership transaction (see Note 11). The note, which is due in February 2024, was initially recorded at its $ 5.7 million present value discounted at a rate of 4.4 %, which is our estimated discount rate for similar instruments. The receivable balance is being accreted to the full receivable amount on a straight-line basis over the remaining receivable term due to its short-term maturity. The receivable balanc e was $ 5.8 million as of March 31, 2023. Also in conjunction with the Vision Bioenergy partnership transaction, S&W received a one-time option, or Purchase Option, exercisable at any time on or before the fifth anniversary of the closing of the partnership transaction, to repurchase a 6 % membership interest from Shell. The option repurchase prices range between approximately $ 7.1 and $ 12.0 million, depending on the date on which such purchase is completed. The Purchase Option was valued at $ 0.6 million using a lattice option valuation model. The valuation model incorporated significant, unobservable inputs including a discounted cash flow model based on management projections of future Vision Bioenergy results and an estimate of the current per share value of Vision Bioenergy shares. In the model, the estimate of the current per share value was discounted to account for lack of control and marketability, which were considered to be part of the unit of account given the restrictions of the limited liability company agreement that governs the ownership rights of the members. Other unobservable inputs included the risk-free rates and the estimated future stock volatility based on the historical stock price volatilities of other market participants. A full fair value analysis will be performed at each fiscal year-end or when there is an indication that there may be an impairment to the valuation. Management will estimate and adjust the balance for interim periods. No adjustment to the fair value was recorded as of March 31, 2023. Quantitative information about Level 3 fair value measurement is as follows: Fair Value at 3/31/23 Valuation Technique Unobservable Input Range Purchase Option $ 604,000 Option Model Risk-free rate 3.8 % - 4.9 % Stock price volatility 60 % - 65 % Lack of control premium 13 % Lack of marketability premium 30 % Assets and liabilities that are recognized and measured at fair value on a recurring basis are categorized as follows: Fair Value Measurements as of March 31, 2023 Using: Level 1 Level 2 Level 3 Foreign exchange contract liability $ — $ 812,362 $ — Vision Bioenergy interest purchase option — — 604,000 Total $ — $ 812,362 $ 604,000 Fair Value Measurements as of June 30, 2022 Using: Level 1 Level 2 Level 3 Foreign exchange contract liability $ — $ 996,106 $ — Total $ — $ 996,106 $ —
Recent Accounting Pronouncements Not Yet Adopted	Recent Accounting Pronouncements Not Yet Adopted We have evaluated all issued and unadopted Accounting Standards Updates and believe the adoption of these standards will not have a material impact on our condensed consolidated statements of operations, comprehensive income, balance sheets, or cash flows.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
Summary of Significant Accounting Policies (Tables)	Mar. 31, 2023
Accounting Policies [Abstract]
Components of Inventory	Components of inventory are as follows: As of As of March 31, 2023 June 30, 2022 Raw materials and supplies $ 3,312,634 $ 2,645,764 Work in progress 12,890,422 6,677,980 Finished goods 39,463,571 45,192,150 Inventories, net $ 55,666,627 $ 54,515,894
Schedule of Calculation of Net Loss Per Common Share	The calculation of net loss per common share is shown in the table below: Three Months Ended March 31, Nine Months Ended March 31, 2023 2022 2023 2022 Numerator: Net income (loss) attributable to S&W Seed Company $ 32,119,365 $ ( 7,304,923 ) $ 21,624,419 $ ( 23,500,000 ) Dividends accrued for participating securities ( 95,299 ) ( 40,276 ) ( 271,746 ) ( 40,276 ) Accretion of Series B Preferred Stock redemption value ( 25,838 ) ( 12,919 ) ( 77,514 ) ( 12,919 ) Numerator for net income (loss) per common share - basic and diluted $ 31,998,228 $ ( 7,358,118 ) $ 21,275,159 $ ( 23,553,195 ) Denominator: Denominator for basic EPS - weighted average shares 42,790,693 39,515,547 42,681,201 38,240,917 Less: weighted average shares - dilutive securities: Employee stock options 182,574 — 60,858 — Employee restricted stock options 192,881 — 131,771 — Denominator for diluted EPS - weighted average shares 43,166,148 39,515,547 42,873,830 38,240,917 Net income (loss) per common share - basic $ 0.75 $ ( 0.19 ) $ 0.50 $ ( 0.62 ) Net income (loss) per common share - diluted $ 0.74 $ ( 0.19 ) $ 0.50 $ ( 0.62 )
Schedule of Assets and Liabilities Recognized and Measured at Fair Value on Recurring Basis	Assets and liabilities that are recognized and measured at fair value on a recurring basis are categorized as follows: Fair Value Measurements as of March 31, 2023 Using: Level 1 Level 2 Level 3 Foreign exchange contract liability $ — $ 812,362 $ — Vision Bioenergy interest purchase option — — 604,000 Total $ — $ 812,362 $ 604,000 Fair Value Measurements as of June 30, 2022 Using: Level 1 Level 2 Level 3 Foreign exchange contract liability $ — $ 996,106 $ — Total $ — $ 996,106 $ —
Schedule of Quantitative Information About Level 3 Fair Value Measurement	Quantitative information about Level 3 fair value measurement is as follows: Fair Value at 3/31/23 Valuation Technique Unobservable Input Range Purchase Option $ 604,000 Option Model Risk-free rate 3.8 % - 4.9 % Stock price volatility 60 % - 65 % Lack of control premium 13 % Lack of marketability premium 30 %

Leases (Tables)

Leases (Tables)	9 Months Ended
Leases (Tables)	Mar. 31, 2023
Lessee Disclosure [Abstract]
Summary of Components of Lease Assets and Liabilities	The components of lease assets and liabilities as of March 31, 2023 and June 30, 2022 are as follows: Leases Balance Sheet Classification: March 31, 2023 June 30, 2022 Assets: Right of use assets - finance leases $ 1,736,128 $ 2,071,609 Accumulated amortization - finance leases ( 1,104,261 ) ( 1,131,842 ) Right of use assets - finance leases, net Other assets 631,867 939,767 Right of use assets - operating leases Right of use assets - operating leases 3,344,109 4,094,253 Total lease assets $ 3,975,976 $ 5,034,020 Liabilities: Current lease liabilities - finance leases Current portion of long-term debt, net $ 402,164 $ 804,309 Current lease liabilities - operating leases Accrued expenses and other current liabilities 1,254,357 1,341,198 Long-term portion of lease liabilities - Long-term debt, net, less current portion 246,977 500,723 Long-term portion of lease liabilities - Other non-current liabilities 2,337,168 3,042,311 Total lease liabilities $ 4,240,666 $ 5,688,541
Summary of Components of Lease Cost	The components of lease cost are as follows: Lease cost: Income Statement Classification: Three Months Ended March 31, 2023 Nine Months Ended March 31, 2023 Operating lease cost Cost of revenue $ 193,011 $ 540,260 Operating lease cost Selling, general and administrative expenses 45,040 155,288 Operating lease cost Research and development expenses 92,016 316,833 Finance lease cost Depreciation and amortization 120,263 385,901 Finance lease cost Interest expense, net 8,714 30,033 Total lease costs $ 459,044 $ 1,428,315
Summary of Maturities of Lease Liabilities	Maturities of lease liabilities as of March 31, 2023, are as follows: Fiscal Year Operating Leases Finance Leases Remainder of 2023 $ 359,999 $ 126,830 2024 1,387,727 367,055 2025 978,126 144,272 2026 641,966 51,829 2027 400,807 - Thereafter 102,974 - Total lease payments 3,871,599 689,986 Less: Interest ( 280,074 ) ( 40,845 ) Present value of lease liabilities $ 3,591,525 $ 649,141
Summary of Weighted Average Assumptions on Lease Term and Discount Rate and Supplemental Cash Flow Information Related to Leases	The following are the weighted average assumptions used for lease term and discount rate and supplemental cash flow information related to leases as of March 31, 2023: Operating lease remaining lease term 3.3 years Operating lease discount rate 4.14 % Finance lease remaining lease term 1.1 years Finance lease discount rate 6.04 % Cash paid for operating leases $ 1,063,242 Cash paid for finance leases 490,810

Revenue Recognition (Tables)

Revenue Recognition (Tables)	9 Months Ended
Revenue Recognition (Tables)	Mar. 31, 2023
Revenues [Abstract]
Schedule of disaggregation of revenues	The Company disaggregates revenue by type of contract and by destination country. The following table shows revenue from external sources by type of contract: Three Months Ended March 31, Nine Months Ended March 31, 2023 2022 2023 2022 Seed sales $ 17,382,360 $ 22,791,148 $ 50,054,978 $ 49,946,635 Services 279,947 395,729 410,996 1,403,332 Total revenue $ 17,662,307 $ 23,186,877 $ 50,465,974 $ 51,349,967
Schedule of Revenues and Percentage of Revenue from External Customers by Country	The following tables show revenue and percentage of revenue from external sources by destination country: Three Months Ended March 31, Nine Months Ended March 31, 2023 2022 2023 2022 United States $ 8,035,365 45 % $ 9,270,851 40 % $ 12,751,506 25 % $ 15,340,257 30 % Australia 7,336,338 42 % 8,846,660 38 % 12,522,642 25 % 14,526,512 28 % Saudi Arabia 292,150 2 % 1,168,502 5 % 7,631,494 15 % 6,316,258 12 % Mexico 482,300 3 % 602,060 3 % 4,297,823 8 % 2,833,622 6 % Libya — 0 % 929,335 4 % 2,995,608 6 % 1,668,044 3 % Sudan — 0 % 265,292 1 % 2,303,702 5 % 1,644,073 3 % Pakistan 240,935 1 % — 0 % 1,594,026 3 % 1,409,147 3 % South Africa ( 751 ) 0 % — 0 % 1,063,255 2 % 1,088,000 2 % Algeria 176,000 1 % 557,510 2 % 912,040 2 % 959,810 2 % Argentina ( 3,188 ) 0 % — 0 % 803,264 2 % 819,618 2 % Other 1,103,158 6 % 1,546,667 7 % 3,590,614 7 % 4,744,626 9 % Total revenue $ 17,662,307 100 % $ 23,186,877 100 % $ 50,465,974 100 % $ 51,349,967 100 %

Intangible Assets (Tables)

Intangible Assets (Tables)	9 Months Ended
Intangible Assets (Tables)	Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	Intangible assets consist of the following: Balance at Other Additions and Disposals Amortization Currency Translation Adjustment Balance at March 31, 2023 Trade name $ 1,084,791 $ — $ ( 147,630 ) $ ( 5,737 ) $ 931,424 Customer relationships 5,499,815 — ( 265,258 ) ( 131,244 ) 5,103,313 GI customer list 42,983 — ( 5,373 ) — 37,610 Supply agreement 775,241 — ( 56,725 ) — 718,516 Grower relationships 1,331,581 — ( 79,055 ) — 1,252,526 Intellectual property 23,035,925 — ( 1,039,162 ) — 21,996,763 License agreement 1,986,598 ( 1,885,907 ) ( 75,610 ) ( 25,081 ) ( 0 ) Internal use software 338,893 — ( 50,833 ) — 288,060 $ 34,095,827 $ ( 1,885,907 ) $ ( 1,719,646 ) $ ( 162,062 ) $ 30,328,212 Balance at Other Additions and Disposals Amortization Currency Translation Adjustment Balance at Trade name $ 1,310,489 $ — $ ( 203,009 ) $ ( 22,689 ) $ 1,084,791 Customer relationships 6,302,591 — ( 373,393 ) ( 429,383 ) 5,499,815 Non-compete 5,058 — ( 5,058 ) — — GI customer list 50,146 — ( 7,163 ) — 42,983 Supply agreement 850,874 — ( 75,633 ) — 775,241 Grower relationships 1,436,988 — ( 105,407 ) — 1,331,581 Intellectual property 24,427,857 — ( 1,391,932 ) — 23,035,925 License agreement 2,340,269 — ( 172,004 ) ( 181,667 ) 1,986,598 Internal use software 406,670 — ( 67,777 ) — 338,893 $ 37,130,942 $ — $ ( 2,401,376 ) $ ( 633,739 ) $ 34,095,827
Intangible Assets (Future Amortization)	Estimated aggregate remaining amortization is as follows: 2023 2024 2025 2026 2027 Thereafter Amortization expense $ 527,879 $ 2,154,690 $ 2,114,725 $ 1,975,491 $ 1,924,607 $ 21,630,820

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	9 Months Ended
Property, Plant and Equipment (Tables)	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Components of Property, Plant and Equipment	Components of property, plant and equipment were as follows: As of As of March 31, 2023 June 30, 2022 Land and improvements $ 942,919 $ 2,265,087 Buildings and improvements 3,371,017 8,119,960 Machinery and equipment 12,622,765 14,972,462 Vehicles 608,002 1,085,342 Leasehold improvements 552,810 552,810 Construction in progress 20,000 110,107 Total property, plant and equipment 18,117,513 27,105,768 Less: accumulated depreciation ( 7,875,828 ) ( 10,234,099 ) Property, plant and equipment, net $ 10,241,685 $ 16,871,669

Debt (Tables)

Debt (Tables)	9 Months Ended
Debt (Tables)	Mar. 31, 2023
Debt Disclosure [Abstract]
Schedule of Total Debt Outstanding	Total debt outstanding is presented on the consolidated balance sheet as follows: March 31, 2023 June 30, 2022 Current portion of working capital lines of credit CIBC $ 18,279,289 $ 12,804,611 National Australia Bank Limited 24,771,500 338,314 Debt issuance costs ( 267,653 ) ( 464,028 ) Total current portion of working capital lines of credit, net 42,783,136 12,678,897 Long-term portion of working capital lines of credit, less current portion National Australia Bank Limited — 21,703,286 Total long-term portion of working capital lines of credit — 21,703,286 Total working capital lines of credit, net $ 42,783,136 $ 34,382,183 Current portion of long-term debt Finance leases $ 402,164 $ 804,309 Term Loan - National Australia Bank Limited 334,750 344,400 Machinery & equipment loans - National Australia Bank Limited 257,963 246,547 Machinery & equipment loans - Hyster 11,897 11,834 Vehicle loans - Ford Credit 51,277 40,341 Secured real estate note - Rooster — 6,905,995 Debt issuance costs — ( 36,643 ) Total current portion, net 1,058,051 8,316,783 Long-term debt, less current portion Finance leases 246,977 500,723 Term loan - National Australia Bank Limited 2,343,250 2,410,800 Machinery & equipment loans - National Australia Bank Limited 956,029 963,733 Machinery & equipment loans - Hyster 18,944 28,722 Vehicle loans - Ford Credit 83,532 88,583 Debt issuance costs — ( 21 ) Total long-term portion, net 3,648,732 3,992,540 Total debt, net $ 4,706,783 $ 12,309,323
Schedule of Annual Maturities of Long-Term Debt Excluding Finance Lease Liabilities	The annual maturities of long-term debt, excluding finance lease liabilities, are as follows: Fiscal Year Amount Remainder of 2023 $ 76,909 2024 668,649 2025 632,758 2026 2,330,226 2027 161,420 Thereafter 187,682 Total $ 4,057,644

Equity-Based Compensation (Tabl

Equity-Based Compensation (Tables)	9 Months Ended
Equity-Based Compensation (Tables)	Mar. 31, 2023
Summary of Stock Option Activity	A summary of stock option activity for the nine months ended March 31, 2023 and the year ended June 30, 2022 is presented below: Number of Weighted - Weighted- Aggregate Outstanding at June 30, 2021 3,776,568 $ 2.65 8.0 $ 3,962,766 Granted 994,725 2.63 Exercised ( 38,774 ) 2.33 Canceled/forfeited/expired ( 95,419 ) 2.82 Outstanding at June 30, 2022 4,637,100 $ 2.64 6.6 $ — Granted 1,289,675 1.26 Exercised ( 1,050 ) 0.95 Canceled/forfeited/expired ( 844,545 ) 2.79 Outstanding at March 31, 2023 5,081,180 $ 2.27 7.2 $ 459,346 Options vested and exercisable at March 31, 2023 3,235,391 $ 2.59 6.1 $ 39,501 Options vested and expected to vest as of March 31, 2023 5,071,515 $ 2.27 7.2 $ 455,713
Summary of Activity Related to Non-Vested Restricted Stock Units	A summary of activity related to non-vested restricted stock units is presented below: Number of Weighted-Average Weighted-Average Nonvested restricted units outstanding at June 30, 2021 361,570 $ 2.51 1.3 Granted 304,421 2.78 — Vested ( 391,036 ) 2.62 — Forfeited ( 7,036 ) 2.35 — Nonvested restricted units outstanding at June 30, 2022 267,919 $ 2.66 1.2 Granted 495,196 1.14 1.6 Vested ( 224,164 ) 2.55 — Forfeited ( 8,750 ) 2.50 — Nonvested restricted units outstanding at March 31, 2023 530,201 $ 1.29 1.7
Schedule of Weighted Average Assumptions Used in Black-Scholes-Merton Model	Weighted-average assumptions used in the Black-Scholes-Merton model are set forth below for the periods indicated: March 31, 2023 March 31, 2022 Risk free rate 2.9 % - 4.4 % 0.8 % - 1.1 % Dividend yield — — Volatility 64.7 % - 66.1 % 61.8 % - 63.8 % Average forfeiture assumptions 8.2 % 2.8 %

Investments (Tables)

Investments (Tables)	9 Months Ended
Investments (Tables)	Mar. 31, 2023
Schedule of Equity Method Investments [Line Items]
Schedule of Gain on Equity Method Investments	This consideration is summarized below: Equity investment $ 23,664,195 Cash 7,000,000 Debt retirement 6,840,879 Present value of future payment 5,747,126 Fixed assets and inventory transfer ( 5,532,694 ) Fair value of 6 % member purchase option 604,000 Gain on equity method investments $ 38,323,506 Vision
Vision Bioenergy
Schedule of Equity Method Investments [Line Items]
Summary of Equity Method Investments	The summarized unaudited balance sheet presented below reflects the financial information of Vision Bioenergy as of March 31, 2023: As of March 31, 2023 Cash $ 11,042,929 Other current assets 432,992 Fixed assets 14,385,791 Intangible assets 17,820,005 Goodwill 14,006,268 Other assets 165,796 TOTAL ASSETS $ 57,853,781 Current liabilities 581,549 Long-term liabilities 117,492 Equity 57,154,740 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 57,853,781 The summarized unaudited income statement presented below reflects the financial information of Vision Bioenergy for the three and nine months ended March 31, 2023: Three and Nine Months Ended March 31, 2023 Revenue $ 83,505 Gross profit (loss) ( 206,985 ) Loss from operations ( 953,718 ) Net loss ( 951,582 )
Bioceres
Schedule of Equity Method Investments [Line Items]
Summary of Equity Method Investments	The following summarizes the carrying amount of the Company's equity method investments reflected in the consolidated balance sheet: March 31, 2023 June 30, 2022 Carrying Amount Economic Interest Carrying Amount Economic Interest Vision Bioenergy $ 23,340,657 34 % $ — 0 % Trigall Australia 781,114 20 % — 0 % Bioceres — 0 % 367,970 1 % Total equity method investments $ 24,121,771 $ 367,970

Series B Convertible Preferre_2

Series B Convertible Preferred Stock (Tables)	9 Months Ended
Series B Convertible Preferred Stock (Tables)	Mar. 31, 2023
Temporary Equity Disclosure [Abstract]
Summary of Changes to Series B Convertible Preferred Stock	The following summarizes changes to the Series B Convertible Preferred Stock: Balance at June 30, 2021 $ — Issuance of preferred stock 4,638,521 Dividends accrued 127,541 Accretion of discount for warrants 38,757 Balance at June 30, 2022 $ 4,804,819 Dividends accrued 271,746 Accretion of discount for warrants 77,514 Balance at March 31, 2023 $ 5,154,079

Non-Cash Activities for State_2

Non-Cash Activities for Statements of Cash Flows (Tables)	9 Months Ended
Non-Cash Activities for Statements of Cash Flows (Tables)	Mar. 31, 2023
Supplemental Cash Flow Elements [Abstract]
Schedule of Condensed Consolidated Statements of Cash Flows for Non-Cash Activities	The below table represents supplemental information to the Company’s condensed consolidated statements of cash flows for non-cash activities during the nine months ended March 31, 2023 and 2022, respectively. Nine Months Ended March 31, 2023 2022 Non-cash investing activities: ROU assets financed by lease liabilities $ 498,143 $ 271,524 Consideration received from Shell for equity interest in Vision Bioenergy: Settlement of long-term debt principal, interest and other related costs 6,840,879 — Note receivable 5,747,127 — Membership purchase option 604,000 — Contribution of property, plant and equipment and inventory to Vision Bioenergy for equity interest ( 5,532,694 ) — Contribution of intangible assets to Trigall in exchange for equity investment and promissory note ( 1,750,000 ) — Non-cash financing activities: Warrants issued for financial commitment asset 1,894,901 — Dividends accrued for participating securities 271,746 40,276 Accretion of discount for Series B preferred stock warrants 77,514 12,919

General - Additional Informatio

General - Additional Information (Details) - USD ($)	3 Months Ended	9 Months Ended
General - Additional Information (Details) - USD ($)	Mar. 31, 2022	Mar. 31, 2023	Feb. 06, 2023	Dec. 23, 2022	Jun. 30, 2022
Background And Organizations [Line Items]
Percentage of sale of investment in Bioceres, S.A.	71.40%
Net proceeds from sale of marketable securities	$ 988,504	$ 400,000
Gain on sale of marketable securities	$ 68,967	$ 32,030
Trigall Australia Pty Ltd
Background And Organizations [Line Items]
Investment ownership percentage		20%		20%	0%
Vision Bioenergy
Background And Organizations [Line Items]
Investment ownership percentage		34%	34%		0%
Shell \| Vision Bioenergy
Background And Organizations [Line Items]
Investment ownership percentage			66%
Shell \| Trigall Australia Pty Ltd
Background And Organizations [Line Items]
Investment ownership percentage				80%
Equity Method Investments
Background And Organizations [Line Items]
Carrying value of investment					$ 367,970

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Details)						1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Mar. 22, 2023	Feb. 06, 2023 USD ($)	Dec. 23, 2022	Sep. 22, 2022	Dec. 26, 2019	Mar. 31, 2023 USD ($)	Mar. 31, 2023 USD ($) Customer	Mar. 31, 2022 USD ($) Customer	Mar. 31, 2023 USD ($) Customer shares	Mar. 31, 2022 USD ($) Customer	Jun. 30, 2022 USD ($) Customer	Feb. 08, 2023 USD ($)
Summary Of Significant Accounting Policies [Line Items]
Line of credit facility, remaining borrowing capacity						$ 1,800,000	$ 1,800,000		$ 1,800,000
Cash balances						879,542	879,542		$ 879,542		$ 994,957
Disclosure on Geographic Areas, Fixed Assets									The net book value of fixed assets located outside the United States was 31% and 22% of total fixed assets on March 31, 2023 and June 30, 2022, respectively. Cash balances located outside of the United States may not be insured and totaled $439,920 and $811,551 on March 31, 2023 and June 30, 2022, respectively. Cash balances residing in the United States exceeding the Federal Deposit Insurance Corporation limit of $250,000 totaled $879,542 and $994,957 on March 31, 2023 and June 30, 2022, respectively.
Employee retention credit relief						1,400,000
Owe tax advisory costs upon relief						200,000
Net income (loss)							32,113,573	$ (7,262,255)	$ 21,607,777	$ (23,458,061)
Net cash used in operations									15,828,395	18,006,419
Cash on hand						1,600,000	1,600,000		1,600,000
Facility outstanding amount											34,382,183
Government grant income							1,444,044	0	1,444,044	0
Allowance for doubtful trade receivables						258,821	258,821		258,821		$ 233,927
Dividends accrued undistributed earnings to allocate to participating securities							0	0	0	0
Foreign currency loss							331,889	$ 146,935	699,428	$ 567,963
Federal deposit cash						250,000	250,000		250,000
Other Expense (Income)
Summary Of Significant Accounting Policies [Line Items]
Foreign currency loss							300,000		700,000
Cost of Revenue
Summary Of Significant Accounting Policies [Line Items]
Foreign currency loss							400,000		600,000
Shell
Summary Of Significant Accounting Policies [Line Items]
Membership interest repurchase percent		6%
Receivables discount rate		4.40%
Receivable		$ 5,700,000
Notes receivable						5,800,000	5,800,000		$ 5,800,000
Fair market value of purchase option		600,000
Employee Stock Options
Summary Of Significant Accounting Policies [Line Items]
Anti-dilutive shares, excluded from computation of diluted income (loss) per share \| shares									4,319,232
Series B Convertible Preferred Stock
Summary Of Significant Accounting Policies [Line Items]
Anti-dilutive shares, excluded from computation of diluted income (loss) per share \| shares									1,695,000
Shares of Common Stock Related to MFP Loan Agreement
Summary Of Significant Accounting Policies [Line Items]
Anti-dilutive shares, excluded from computation of diluted income (loss) per share \| shares									2,633,400
Warrants Issued with Series B Convertible Preferred Stock
Summary Of Significant Accounting Policies [Line Items]
Anti-dilutive shares, excluded from computation of diluted income (loss) per share \| shares									559,350
Restricted Stock Units (RSUs)
Summary Of Significant Accounting Policies [Line Items]
Anti-dilutive shares, excluded from computation of diluted income (loss) per share \| shares									48,439
Minimum \| Shell
Summary Of Significant Accounting Policies [Line Items]
Membership interest repurchase price		7,100,000
Maximum \| Shell
Summary Of Significant Accounting Policies [Line Items]
Additional proceeds to be received from sale of businesses in one year		6,000,000
Membership interest repurchase price		$ 12,000,000
CIBC
Summary Of Significant Accounting Policies [Line Items]
Line of credit facility, remaining borrowing capacity						1	1		$ 1
Facility outstanding amount						$ 18,300,000	$ 18,300,000		$ 18,300,000
Debt instrument, maturity date	Aug. 31, 2024		Mar. 23, 2023		Dec. 23, 2022
Conterra
Summary Of Significant Accounting Policies [Line Items]
Debt instrument, maturity date			Mar. 01, 2023	Dec. 23, 2022
Line of Credit \| CIBC
Summary Of Significant Accounting Policies [Line Items]
Net due from related entities covenant maximum												$ 18,500,000
Non-US
Summary Of Significant Accounting Policies [Line Items]
Concentration of risk fixed assets amount geographic area, percent of total						31%	31%		31%		22%
Cash balances						$ 439,920	$ 439,920		$ 439,920		$ 811,551
Customer Concentration Risk \| Revenue
Summary Of Significant Accounting Policies [Line Items]
Number of customers \| Customer							0	0	0	0
Customer Concentration Risk \| Significant Customer \| Revenue \| Minimum
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage							10%	10%	10%	10%
Customer Concentration Risk \| Significant Customer \| Accounts Receivable \| Minimum
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage									10%		10%
Credit Concentration Risk \| Accounts Receivable
Summary Of Significant Accounting Policies [Line Items]
Number of customers \| Customer									0		0
Geographic Concentration Risk \| Revenue \| Non-US
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage							55%	60%	75%	70%
B Riley Securities Incorporated [Member] \| ATM Agreement
Summary Of Significant Accounting Policies [Line Items]
Value of remaining common stock available to sell under agreement						$ 6,200,000	$ 6,200,000		$ 6,200,000

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Components of Inventory (Details) - USD ($)	Mar. 31, 2023	Jun. 30, 2022
Inventory Disclosure [Abstract]
Raw materials and supplies	$ 3,312,634	$ 2,645,764
Work in progress	12,890,422	6,677,980
Finished goods	39,463,571	45,192,150
Inventories, net	$ 55,666,627	$ 54,515,894

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Schedule of Calculation of Net Loss Per Common Share (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2022
Numerator:
Net income (loss) attributable to S&W Seed Company	$ 32,119,365	$ (7,304,923)	$ 21,624,419	$ (23,500,000)
Dividends accrued for participating securities	(95,299)	(40,276)	(271,746)	(40,276)	$ (127,541)
Accretion of Series B Preferred Stock redemption value	(25,838)	(12,919)	(77,514)	(12,919)
Numerator for net income (loss) per common share - basic and diluted	$ 31,998,228	$ (7,358,118)	$ 21,275,159	$ (23,553,195)
Denominator:
Denominator for basic EPS - weighted average shares	42,790,693	39,515,547	42,681,201	38,240,917
Less: weighted average shares - dilutive securities:
Denominator for diluted EPS - weighted average shares	43,166,148	39,515,547	42,873,830	38,240,917
Net income (loss) per common share - basic	$ 0.75	$ (0.19)	$ 0.50	$ (0.62)
Net income (loss) per common share - diluted	$ 0.74	$ (0.19)	$ 0.50	$ (0.62)
Restricted Stock [Member]
Less: weighted average shares - dilutive securities:
Employee stock options	192,881		131,771
Employee Stock [Member]
Less: weighted average shares - dilutive securities:
Employee stock options	182,574		60,858

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Schedule of Quantitative Information About Level 3 Fair Value Measurement (Details)	Mar. 31, 2023 USD ($)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Asset, Valuation Technique [Extensible Enumeration]	us-gaap:ValuationTechniqueOptionPricingModelMember
Level 3
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Purchase option	$ 604,000
Risk-free rate \| Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Key inputs used in valuation	0.049
Risk-free rate \| Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Key inputs used in valuation	0.038
Stock price volatility \| Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Key inputs used in valuation	0.65
Stock price volatility \| Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Key inputs used in valuation	0.60
Lack of control premium
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Key inputs used in valuation	0.13
Lack of marketability premium
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Key inputs used in valuation	0.30

Summary of Significant Accoun_8

Summary of Significant Accounting Policies - Schedule of Assets and Liabilities Recognized and Measured at Fair Value on Recurring Basis (Details) - USD ($)	Mar. 31, 2023	Jun. 30, 2022
Level 1
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Foreign exchange contract liability	$ 0	$ 0
Vision Bioenergy interest purchase option	0
Total	0	0
Level 2
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Foreign exchange contract liability	812,362	996,106
Vision Bioenergy interest purchase option	0
Total	812,362	996,106
Level 3
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Foreign exchange contract liability	0	0
Vision Bioenergy interest purchase option	604,000
Total	$ 604,000	$ 0

Leases - Summary of Components

Leases - Summary of Components of Lease Assets and Liabilities (Details) - USD ($)	Mar. 31, 2023	Jun. 30, 2022
Lessee Disclosure [Abstract]
Right of use assets - finance leases	$ 1,736,128	$ 2,071,609
Accumulated amortization - finance leases	(1,104,261)	(1,131,842)
Right of use assets - finance leases, net	$ 631,867	$ 939,767
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	Other assets	Other assets
Right of use assets - operating leases	$ 3,344,109	$ 4,094,253
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	Right of use assets - operating leases	Right of use assets - operating leases
Total lease assets	$ 3,975,976	$ 5,034,020
Current lease liabilities - finance leases	$ 402,164	$ 804,309
Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]	Current portion of long-term debt, net	Current portion of long-term debt, net
Current lease liabilities - operating leases	$ 1,254,357	$ 1,341,198
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	Accrued expenses and other current liabilities	Accrued expenses and other current liabilities
Long-term portion of lease liabilities - finance leases	$ 246,977	$ 500,723
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Long-term debt, net, less current portion	Long-term debt, net, less current portion
Long-term portion of lease liabilities - operating leases	$ 2,337,168	$ 3,042,311
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Other non-current liabilities	Other non-current liabilities
Total lease liabilities	$ 4,240,666	$ 5,688,541

Leases - Summary of Component_2

Leases - Summary of Components of Lease Cost (Details) - USD ($)	3 Months Ended	9 Months Ended
	Mar. 31, 2023	Mar. 31, 2023
Lessee Lease Description [Line Items]
Total lease costs	$ 459,044	$ 1,428,315
Cost of Revenue
Lessee Lease Description [Line Items]
Operating lease cost	193,011	540,260
Selling, General and Administrative Expenses
Lessee Lease Description [Line Items]
Operating lease cost	45,040	155,288
Research and Development Expenses
Lessee Lease Description [Line Items]
Operating lease cost	92,016	316,833
Depreciation and Amortization
Lessee Lease Description [Line Items]
Finance lease cost	120,263	385,901
Interest Expense
Lessee Lease Description [Line Items]
Finance lease cost	$ 8,714	$ 30,033

Leases - Summary of Maturities

Leases - Summary of Maturities of Lease Liabilities (Details)	Mar. 31, 2023 USD ($)
Operating Leases
Remainder of 2023	$ 359,999
2024	1,387,727
2025	978,126
2026	641,966
2027	400,807
Thereafter	102,974
Total lease payments	3,871,599
Less: Interest	(280,074)
Present value of lease liabilities	3,591,525
Finance Leases
Remainder of 2023	126,830
2024	367,055
2025	144,272
2026	51,829
Total lease payments	689,986
Less: Interest	(40,845)
Present value of lease liabilities	$ 649,141

Leases - Summary of Weighted Av

Leases - Summary of Weighted Average Assumptions on Lease Term and Discount Rate and Supplemental Cash Flow Information Related to Leases (Details)	9 Months Ended
	Mar. 31, 2023 USD ($)
Lessee Disclosure [Abstract]
Operating lease remaining lease term	3 years 3 months 18 days
Operating lease discount rate	4.14%
Finance lease remaining lease term	1 year 1 month 6 days
Finance lease discount rate	6.04%
Cash paid for operating leases	$ 1,063,242
Cash paid for finance leases	$ 490,810

Revenue Recognition - Additiona

Revenue Recognition - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Revenue Recognition [Line Items]
Maximum term of payments for transfer goods and services			1 year
Bad debt expense (reversal)	$ 48,634		$ (76,575)	$ 200,458
Revenue recognized			600,000	400,000
Revenue	17,662,307	$ 23,186,877	50,465,974	51,349,967
Seed Sales
Revenue Recognition [Line Items]
Revenue	17,382,360	22,791,148	$ 50,054,978	49,946,635
ADAMA Collaboration Agreement
Revenue Recognition [Line Items]
Total share value percentage			60%
ADAMA Collaboration Agreement \| Seed Sales
Revenue Recognition [Line Items]
Revenue	$ 3,800,000	$ 1,700,000	$ 5,000,000	$ 1,700,000
ADAMA Collaboration Agreement \| Makhteshim Agan of North America, Inc.
Revenue Recognition [Line Items]
Total share value percentage			40%
Minimum
Revenue Recognition [Line Items]
Term of customer invoice payment			30 days
Maximum
Revenue Recognition [Line Items]
Term of customer invoice payment			180 days
Maximum \| ADAMA Collaboration Agreement
Revenue Recognition [Line Items]
Total share value percentage			100%

Revenue Recognition - Disaggreg

Revenue Recognition - Disaggregation of Revenue (Details) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Disaggregation Of Revenue [Line Items]
Total revenue	$ 17,662,307	$ 23,186,877	$ 50,465,974	$ 51,349,967
Seed Sales
Disaggregation Of Revenue [Line Items]
Total revenue	17,382,360	22,791,148	50,054,978	49,946,635
Services
Disaggregation Of Revenue [Line Items]
Total revenue	$ 279,947	$ 395,729	$ 410,996	$ 1,403,332

Revenue Recognition - Schedule

Revenue Recognition - Schedule of Revenues and Percentage of Revenue from External Customers by Country (Details) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Disaggregation of Revenue [Line Items]
Revenues from external customers	$ 17,662,307	$ 23,186,877	$ 50,465,974	$ 51,349,967
Revenue from external customers by country, percentage	100%	100%	100%	100%
United States
Disaggregation of Revenue [Line Items]
Revenues from external customers	$ 8,035,365	$ 9,270,851	$ 12,751,506	$ 15,340,257
Revenue from external customers by country, percentage	45%	40%	25%	30%
Australia
Disaggregation of Revenue [Line Items]
Revenues from external customers	$ 7,336,338	$ 8,846,660	$ 12,522,642	$ 14,526,512
Revenue from external customers by country, percentage	42%	38%	25%	28%
Saudi Arabia
Disaggregation of Revenue [Line Items]
Revenues from external customers	$ 292,150	$ 1,168,502	$ 7,631,494	$ 6,316,258
Revenue from external customers by country, percentage	2%	5%	15%	12%
Mexico
Disaggregation of Revenue [Line Items]
Revenues from external customers	$ 482,300	$ 602,060	$ 4,297,823	$ 2,833,622
Revenue from external customers by country, percentage	3%	3%	8%	6%
Libya
Disaggregation of Revenue [Line Items]
Revenues from external customers		$ 929,335	$ 2,995,608	$ 1,668,044
Revenue from external customers by country, percentage	0%	4%	6%	3%
Sudan
Disaggregation of Revenue [Line Items]
Revenues from external customers		$ 265,292	$ 2,303,702	$ 1,644,073
Revenue from external customers by country, percentage	0%	1%	5%	3%
Pakistan
Disaggregation of Revenue [Line Items]
Revenues from external customers	$ 240,935		$ 1,594,026	$ 1,409,147
Revenue from external customers by country, percentage	1%	0%	3%	3%
South Africa
Disaggregation of Revenue [Line Items]
Revenues from external customers	$ (751)		$ 1,063,255	$ 1,088,000
Revenue from external customers by country, percentage	0%	0%	2%	2%
Algeria
Disaggregation of Revenue [Line Items]
Revenues from external customers	$ 176,000	$ 557,510	$ 912,040	$ 959,810
Revenue from external customers by country, percentage	1%	2%	2%	2%
Argentina
Disaggregation of Revenue [Line Items]
Revenues from external customers	$ (3,188)		$ 803,264	$ 819,618
Revenue from external customers by country, percentage	0%	0%	2%	2%
Other
Disaggregation of Revenue [Line Items]
Revenues from external customers	$ 1,103,158	$ 1,546,667	$ 3,590,614	$ 4,744,626
Revenue from external customers by country, percentage	6%	7%	7%	9%

Intangible Assets - Additional

Intangible Assets - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 548,438	$ 598,399	$ 1,719,646	$ 1,798,227	$ 2,401,376

Intangible Assets - Schedule of

Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2022
Finite Lived Intangible Assets [Line Items]
Intangible asset			$ 34,095,827	$ 37,130,942	$ 37,130,942
Other Additions and Disposals/ Transfer			(1,885,907)		0
Intangible amortization expense	$ (548,438)	$ (598,399)	(1,719,646)	(1,798,227)	(2,401,376)
Intangible currency translation adjustment			(162,062)		(633,739)
Intangible asset	30,328,212		30,328,212		34,095,827
Trade Name
Finite Lived Intangible Assets [Line Items]
Intangible asset			1,084,791	1,310,489	1,310,489
Other Additions and Disposals/ Transfer			0		0
Intangible amortization expense			(147,630)		(203,009)
Intangible currency translation adjustment			(5,737)		(22,689)
Intangible asset	931,424		931,424		1,084,791
Customer Relationships
Finite Lived Intangible Assets [Line Items]
Intangible asset			5,499,815	6,302,591	6,302,591
Other Additions and Disposals/ Transfer			0		0
Intangible amortization expense			(265,258)		(373,393)
Intangible currency translation adjustment			(131,244)		(429,383)
Intangible asset	5,103,313		5,103,313		5,499,815
Non-compete
Finite Lived Intangible Assets [Line Items]
Intangible asset			0	5,058	5,058
Other Additions and Disposals/ Transfer					0
Intangible amortization expense					(5,058)
Intangible currency translation adjustment					0
Intangible asset					0
GI Customer list
Finite Lived Intangible Assets [Line Items]
Intangible asset			42,983	50,146	50,146
Other Additions and Disposals/ Transfer			0		0
Intangible amortization expense			(5,373)		(7,163)
Intangible currency translation adjustment			0		0
Intangible asset	37,610		37,610		42,983
Supply Agreement
Finite Lived Intangible Assets [Line Items]
Intangible asset			775,241	850,874	850,874
Other Additions and Disposals/ Transfer			0		0
Intangible amortization expense			(56,725)		(75,633)
Intangible currency translation adjustment			0		0
Intangible asset	718,516		718,516		775,241
Grower Relationships
Finite Lived Intangible Assets [Line Items]
Intangible asset			1,331,581	1,436,988	1,436,988
Other Additions and Disposals/ Transfer			0		0
Intangible amortization expense			(79,055)		(105,407)
Intangible currency translation adjustment			0		0
Intangible asset	1,252,526		1,252,526		1,331,581
Intellectual Property
Finite Lived Intangible Assets [Line Items]
Intangible asset			23,035,925	24,427,857	24,427,857
Other Additions and Disposals/ Transfer			0		0
Intangible amortization expense			(1,039,162)		(1,391,932)
Intangible currency translation adjustment			0		0
Intangible asset	21,996,763		21,996,763		23,035,925
License agreement
Finite Lived Intangible Assets [Line Items]
Intangible asset			1,986,598	2,340,269	2,340,269
Other Additions and Disposals/ Transfer			(1,885,907)		0
Intangible amortization expense			(75,610)		(172,004)
Intangible currency translation adjustment			(25,081)		(181,667)
Intangible asset	0		0		1,986,598
Internal use software
Finite Lived Intangible Assets [Line Items]
Intangible asset			338,893	$ 406,670	406,670
Other Additions and Disposals/ Transfer			0		0
Intangible amortization expense			(50,833)		(67,777)
Intangible currency translation adjustment			0		0
Intangible asset	$ 288,060		$ 288,060		$ 338,893

Intangible Assets - Intangible

Intangible Assets - Intangible Assets (Future Amortization) (Details)	Mar. 31, 2023 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2023	$ 527,879
2024	2,154,690
2025	2,114,725
2026	1,975,491
2027	1,924,607
Thereafter	$ 21,630,820

Property, Plant and Equipment -

Property, Plant and Equipment - Components of Property, Plant and Equipment (Details) - USD ($)	Mar. 31, 2023	Jun. 30, 2022
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	$ 18,117,513	$ 27,105,768
Less: accumulated depreciation	(7,875,828)	(10,234,099)
Property, plant and equipment, net	10,241,685	16,871,669
Land and improvements
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	942,919	2,265,087
Buildings and improvements
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	3,371,017	8,119,960
Machinery and Equipment
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	12,622,765	14,972,462
Vehicles
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	608,002	1,085,342
Leasehold improvements
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	552,810	552,810
Construction in progress
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	$ 20,000	$ 110,107

Property, Plant and Equipment_2

Property, Plant and Equipment - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 438,505	$ 625,327	$ 1,591,997	$ 1,809,915

Debt - Schedule of Total Debt O

Debt - Schedule of Total Debt Outstanding (Details) - USD ($)	Mar. 31, 2023	Jun. 30, 2022
Current portion of working capital lines of credit
Total current portion of working capital lines of credit, net	$ 42,783,136	$ 12,678,897
Long-term portion of working capital lines of credit, less current portion
Total long-term portion of working capital lines of credit	0	21,703,286
Total working capital lines of credit, net		34,382,183
Current portion of long-term debt
Finance leases, Current	402,164	804,309
Total current portion, net	1,058,051	8,316,783
Long-term debt, less current portion
Finance leases, Noncurrent	246,977	500,723
Total long-term portion, net	3,648,732	3,992,540
Total debt, net	4,706,783	12,309,323
CIBC
Current portion of working capital lines of credit
Total current portion of working capital lines of credit, net	18,279,289	12,804,611
Long-term portion of working capital lines of credit, less current portion
Total working capital lines of credit, net	18,300,000
National Australia Bank Limited
Current portion of working capital lines of credit
Total current portion of working capital lines of credit, net	24,771,500	338,314
Long-term portion of working capital lines of credit, less current portion
Total long-term portion of working capital lines of credit		21,703,286
Total working capital lines of credit, net	42,783,136
CIBC and NAB
Current portion of long-term debt
Debt issuance costs,Current	(267,653)	(464,028)
Term Loan Long Term Current \| National Australia Bank Limited
Current portion of long-term debt
Secured Debt, Current	334,750	344,400
Machinery & Equipment Loans Long Term Current \| National Australia Bank Limited
Current portion of long-term debt
Secured Debt, Current	257,963	246,547
Machinery & Equipment Loans Long Term Current \| Hyster
Current portion of long-term debt
Secured Debt, Current	11,897	11,834
Long-term debt, less current portion
Secured Long-term Debt, Noncurrent	18,944	28,722
Rooster RE Short
Current portion of long-term debt
Debt issuance costs,Current	0	(36,643)
Secured Debt, Current	0	6,905,995
Vehicle Loans \| Ford Credit
Current portion of long-term debt
Secured Debt, Current	51,277	40,341
Long-term debt, less current portion
Secured Long-term Debt, Noncurrent	83,532	88,583
Debt issuance costs, Noncurrent		(21)
Term Loan Long Term Non Current \| National Australia Bank Limited
Long-term debt, less current portion
Secured Long-term Debt, Noncurrent	2,343,250	2,410,800
Machinery & Equipment Loans long Term \| National Australia Bank Limited
Long-term debt, less current portion
Secured Long-term Debt, Noncurrent	$ 956,029	$ 963,733

Debt - CIBC Credit Facility - A

Debt - CIBC Credit Facility - Additional Information (Details) - USD ($)						9 Months Ended
	Mar. 22, 2023	Dec. 23, 2022	Oct. 28, 2022	May 13, 2022	Dec. 26, 2019	Mar. 31, 2023	Sep. 22, 2022
Line Of Credit Facility [Line Items]
Line of credit facility, remaining borrowing capacity						$ 1,800,000
Incurred financing charges associated other lenders totaled						1,500,000
CIBC
Line Of Credit Facility [Line Items]
Line of credit and security agreement date					Dec. 26, 2019
Line of credit facility, maximum borrowing capacity					$ 35,000,000	$ 25,000,000
Debt instrument, maturity date	Aug. 31, 2024	Mar. 23, 2023			Dec. 23, 2022
Line of credit facility, borrowing capacity, description						Availability of funds under the Amended CIBC Credit Facility is subject to a borrowing base equal to (a) up to 85% of eligible domestic accounts receivable, plus (b) up to 90% of eligible foreign accounts receivable, plus (c) up to the lesser of (i) 65% of eligible inventory and (ii) 85% of the appraised net orderly liquidation value of eligible inventory
Debt instrument, debt default, Increase in interest rate per annum	2%
Borrowing base value of an eligible inventory sublimit			$ 12,000,000	$ 9,000,000
Line of credit facility, current borrowing capacity						$ 19,300,000
Line of credit facility, remaining borrowing capacity						1
Increase in line of credit facility						$ 5,700,000
CIBC \| Loan Agreement
Line Of Credit Facility [Line Items]
Debt instrument, maturity date	Aug. 31, 2024
CIBC \| Line of Credit
Line Of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity			$ 21,000,000	$ 18,000,000
Minimum potential liquidity raised to meet covenant compliance							$ 1,000,000
Debt instrument, interest rate						10%
CIBC \| Line of Credit \| Federal Funds Rate
Line Of Credit Facility [Line Items]
Basis spread on variable rate	0.50%
CIBC \| Line of Credit \| Prime Rate
Line Of Credit Facility [Line Items]
Basis spread on variable rate	2%
CIBC \| Maximum
Line Of Credit Facility [Line Items]
Borrowing base in percentage based on eligible domestic accounts receivable	85%
Borrowing base in percentage based on eligible foreign accounts receivable	90%
Borrowing base in percentage based on eligible inventory	65%
Borrowing base in percentage based on liquidation value of the inventory, subject to lender reserves	85%
CIBC \| February 1 to October 31 of Each Year
Line Of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity	$ 25,000,000
CIBC \| November 1 to January 31 of Each Year
Line Of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity	$ 18,000,000

Debt - Rooster Note - Additiona

Debt - Rooster Note - Additional Information (Details) - Conterra - USD ($) $ in Millions	Feb. 06, 2023	Dec. 23, 2022	Sep. 22, 2022	Nov. 30, 2017
Line Of Credit Facility [Line Items]
Debt instrument, maturity date		Mar. 01, 2023	Dec. 23, 2022
Debt instrument, interest rate		9.25%		7.75%
Outstanding principal and accrued interest paid off	$ 6.6

Debt - NAB Facilities - Additio

Debt - NAB Facilities - Additional Information (Details)		9 Months Ended
Debt - NAB Facilities - Additional Information (Details)	Oct. 25, 2022 AUD ($)	Mar. 31, 2023 USD ($)	Mar. 31, 2023 AUD ($)	Mar. 31, 2023 AUD ($)	Feb. 08, 2023 USD ($)	Dec. 31, 2022 AUD ($)	Jun. 30, 2022 USD ($)	Nov. 11, 2021 AUD ($)
Line Of Credit Facility [Line Items]
Facility outstanding amount							$ 34,382,183
Line of credit facility, remaining borrowing capacity		$ 1,800,000
Master Asset Finance Facility
Line Of Credit Facility [Line Items]
Line of credit facility, current borrowing capacity		25,400,000		$ 37,900,000
Line of credit facility, remaining borrowing capacity		800,000		1,300,000
Net due from related entities covenant maximum	$ 25,000,000				$ 18,500,000
National Australia Bank Limited
Line Of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity		10,000,000		15,000,000
Facility outstanding amount		42,783,136
National Australia Bank Limited \| Borrowing Base Line
Line Of Credit Facility [Line Items]
Line of credit facility, termination date	Sep. 30, 2024
Line of credit facility, expiration extended period	1 year
National Australia Bank Limited \| Borrowing Base Line \| Minimum
Line Of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity		21,400,000						$ 32,000,000
National Australia Bank Limited \| Borrowing Base Line \| Maximum
Line Of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity		26,800,000				$ 40,000,000
National Australia Bank Limited \| Overdraft Credit
Line Of Credit Facility [Line Items]
Line of credit facility, termination date	Sep. 29, 2023
Line of credit facility, expiration extended period	1 year
National Australia Bank Limited \| Overdraft Credit \| Minimum
Line Of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity		700,000						$ 1,000,000
National Australia Bank Limited \| Overdraft Credit \| Maximum
Line Of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity	$ 2,000,000	1,300,000
National Australia Bank Limited \| Master Asset Finance Facility
Line Of Credit Facility [Line Items]
Line of credit facility, termination date	Sep. 29, 2023
Line of credit facility, expiration extended period	1 year
National Australia Bank Ltd Facility
Line Of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity		32,800,000		49,000,000
Increase in line of credit facility		2,700,000	$ 4,100,000
National Australia Bank Ltd Facility \| Maximum
Line Of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity		$ 28,600,000		$ 42,000,000
National Australia Bank Ltd Facility \| Line of Credit
Line Of Credit Facility [Line Items]
Net due from related entities covenant maximum	$ 25,000,000

Debt - MFP Loan Agreement - Add

Debt - MFP Loan Agreement - Additional Information (Details) - USD ($)					3 Months Ended	9 Months Ended
	Mar. 22, 2023	Dec. 23, 2022	Oct. 28, 2022	Sep. 22, 2022	Mar. 31, 2023	Mar. 31, 2023
Line of Credit Facility [Line Items]
Subordinated loan & security agreement warrants					$ 1,092,000	$ 1,894,901
Standby Letters of Credit
Line of Credit Facility [Line Items]
Debt face amount			$ 12,000,000	$ 9,000,000
Debt instrument, maturity date	Sep. 30, 2024	Apr. 30, 2023	Sep. 30, 2024	Jan. 23, 2023
Line of credit facility, maximum borrowing capacity			$ 13,000,000
Standby Letters of Credit \| Minimum
Line of Credit Facility [Line Items]
Line of credit facility, unused capacity commitment fee percentage	3.50%
Standby Letters of Credit \| Maximum
Line of Credit Facility [Line Items]
Line of credit facility, unused capacity commitment fee percentage	4.25%
MFP Loan Agreement
Line of Credit Facility [Line Items]
Debt instrument, maturity date	Nov. 30, 2025
Line of credit facility, maximum borrowing capacity			$ 12,000,000	$ 9,000,000
Line of credit facility, unused capacity commitment fee percentage				3.50%
Debt instrument, percentage of interest payable in cash				50%
Debt instrument, percentage of interest paid in kind				50%
Warrant exercise price per share	$ 2.15		$ 1.60	$ 1.60
Warrant expiration term	5 years		5 years	5 years
MFP Loan Agreement \| Maximum
Line of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity	$ 13,000,000
MFP Loan Agreement \| Letter of Credit
Line of Credit Facility [Line Items]
Debt instrument, maturity date				Jan. 23, 2023
MFP Loan Agreement \| Reference Rate Floor
Line of Credit Facility [Line Items]
Debt instrument, interest rate				1.25%
MFP Loan Agreement \| SOFR
Line of Credit Facility [Line Items]
Basis spread on variable rate				9.25%

Debt - Schedule of Annual Matur

Debt - Schedule of Annual Maturities of Long-Term Debt Excluding Finance Lease Liabilites (Details)	Mar. 31, 2023 USD ($)
Debt Disclosure [Abstract]
Remainder of 2023	$ 76,909
2024	668,649
2025	632,758
2026	2,330,226
2027	161,420
Thereafter	187,682
Total	$ 4,057,644

Foreign Currency Forward Cont_2

Foreign Currency Forward Contracts and Options - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2022
Foreign Currency Forward Contracts and Options [Line Items]
Foreign exchange contract liability	$ 812,362		$ 812,362		$ 996,106
Gains (losses) on foreign exchange contracts	(331,889)	$ (146,935)	(699,428)	$ (567,963)
Options intrinsic value	0		0
Prepaid Expenses and Other Current Assets
Foreign Currency Forward Contracts and Options [Line Items]
Option premiums value	31,055		31,055
Foreign Currency Forward Contracts
Foreign Currency Forward Contracts and Options [Line Items]
Foreign currency forward contracts, notional value	10,621,155		10,621,155
Gains (losses) on foreign exchange contracts	187,154	$ 201,188	$ 167,688	$ 50,971
Foreign Currency Forward Contracts \| Minimum
Foreign Currency Forward Contracts and Options [Line Items]
Foreign currency maturity term			Apr. 30, 2023
Foreign Currency Forward Contracts \| Maximum
Foreign Currency Forward Contracts and Options [Line Items]
Foreign currency maturity term			Jun. 30, 2023
Foreign Currency Options
Foreign Currency Forward Contracts and Options [Line Items]
Foreign currency forward contracts, notional value	$ 9,000,000		$ 9,000,000

Equity - Additional Information

Equity - Additional Information (Details) - USD ($)				3 Months Ended	9 Months Ended
Equity - Additional Information (Details) - USD ($)	Mar. 22, 2023	Oct. 28, 2022	Sep. 22, 2022	Mar. 31, 2023	Mar. 31, 2023	Mar. 31, 2022	Dec. 22, 2022	May 17, 2022	Sep. 23, 2020
MFP Loan Agreement
Class Of Stock [Line Items]
Warrants to purchase of common stock	1,300,000	166,700	500,000	2,633,400	2,633,400		666,700
Warrant exercise price per share	$ 2.15	$ 1.60	$ 1.60
Warrant expiration term	5 years	5 years	5 years
Warrants capitalized					$ 1,894,901
Interest expense amortized					626,141
ATM Agreement \| B. Riley Securities, Inc
Class Of Stock [Line Items]
Maximum aggregate offering price of common stock by agent								$ 24,600,000	$ 17,100,000
Gross proceeds from sale of common stock				$ 200,000	$ 6,200,000	$ 6,200,000
Number of common stock shares issued during the period				102,455	2,633,052	2,633,900
Value of remaining common stock available to sell under agreement				$ 6,200,000	$ 6,200,000

Equity-Based Compensation - Add

Equity-Based Compensation - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options granted			1,289,675
Stock-based compensation, total compensation cost not yet recognized, period for recognition			1 year 4 months 28 days
Stock-based compensation	$ 620,887	$ 413,293	$ 1,382,895	$ 1,821,808
Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation, total compensation cost not yet recognized, period for recognition			1 year 6 months 3 days
Number of restricted stock units issued			495,196		304,421
Fair value of awards granted			$ 563,446	$ 829,780
Unrecognized stock compensation expense related to restricted stock grants	$ 461,652		$ 461,652
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price, upper range Limit			$ 1.89
Maximum \| Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period			3 years
Maximum \| Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period			3 years
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price, lower range limit			$ 0.81
Minimum \| Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period			1 year
Minimum \| Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period			1 year
2019 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares available for issuance of grants	1,642,198		1,642,198
2009 and 2019 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted, weighted average grant date fair value	$ 0.70		$ 0.70
Unrecognized stock compensation expense, net of estimated forfeitures, related to options	$ 1,131,866		$ 1,131,866

Equity-Based Compensation - Sum

Equity-Based Compensation - Summary Of Stock Option Activity (Details) - USD ($)	9 Months Ended	12 Months Ended
	Mar. 31, 2023	Jun. 30, 2022	Jun. 30, 2021
Share-Based Payment Arrangement [Abstract]
Options, Outstanding as of beginning of period	4,637,100	3,776,568
Options, Granted	1,289,675	994,725
Options, Exercised	(1,050)	(38,774)
Options, Canceled/forfeited/expired	(844,545)	(95,419)
Options, Outstanding as of end of period	5,081,180	4,637,100	3,776,568
Options, vested and exercisable at end of period	3,235,391
Options, vested and expected to vest	5,071,515
Weighted-Average Exercise Prices, Outstanding as of beginning of period	$ 2.64	$ 2.65
Weighted-Average Exercise Prices, Granted	1.26	2.63
Weighted-Average Exercise Prices, Exercised	0.95	2.33
Weighted-Average Exercise Prices, Canceled/forfeited/expired	2.79	2.82
Weighted-Average Exercise Prices, Outstanding as of end of period	2.27	$ 2.64	$ 2.65
Weighted-Average Exercise Prices, vested and exercisable	2.59
Weighted-Average Exercise Price, vested and expected to vest	$ 2.27
Options Outstanding, Weighted-Average Remaining Contractual Term (in years)	7 years 2 months 12 days	6 years 7 months 6 days	8 years
Weighted-Average Remaining Contractual Term (in years), vested and exercisable	6 years 1 month 6 days
Weighted-Average Remaining Contractual Term (in years), vested and expected to vest	7 years 2 months 12 days
Options, Outstanding, Aggregate Intrinsic Value	$ 459,346		$ 3,962,766
Options, vested and exercisable, Aggregate Intrinsic Value	39,501
Options, vested and expected to vest, Aggregate Intrinsic Value	$ 455,713

Equity-Based Compensation - S_2

Equity-Based Compensation - Summary of Activity Related to Non-Vested Restricted Stock Units (Details) - Restricted Stock Units - $ / shares	9 Months Ended	12 Months Ended
	Mar. 31, 2023	Jun. 30, 2022	Jun. 30, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Nonvested Restricted Stock Units Outstanding, Beginning	267,919	361,570
Number of Nonvested Restricted Stock Units, Granted	495,196	304,421
Number of Nonvested Restricted Stock Units, Vested	(224,164)	(391,036)
Number of Nonvested Restricted Stock Units, Forfeited	(8,750)	(7,036)
Number of Nonvested Restricted Stock Units Outstanding, Ending	530,201	267,919	361,570
Weighted-Average Grant Date Fair Value, Beginning	$ 2.66	$ 2.51
Weighted-Average Grant Date Fair Value, Granted	1.14	2.78
Weighted-Average Grant Date Fair Value, Vested	2.55	2.62
Weighted-Average Grant Date Fair Value, Forfeited	2.50	2.35
Weighted-Average Grant Date Fair Value, Ending	$ 1.29	$ 2.66	$ 2.51
Weighted-Average Remaining Contractual Life (Years)	1 year 8 months 12 days	1 year 2 months 12 days	1 year 3 months 18 days
Weighted-Average Remaining Contractual Life (Years), Granted	1 year 7 months 6 days

Equity-Based Compensation - Sch

Equity-Based Compensation - Schedule of Weighted Average Assumptions (Details)	9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk free rate, minimum	2.90%	0.80%
Risk free rate, maximum	4.40%	1.10%
Volatility, minimum	64.70%	61.80%
Volatility, maximum	66.10%	63.80%
Average forfeiture assumptions	8.20%	2.80%

Investments - Additional Inform

Investments - Additional Information (Details) - USD ($)			3 Months Ended		9 Months Ended
Investments - Additional Information (Details) - USD ($)	Feb. 06, 2023	Dec. 23, 2022	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2022
Schedule of Equity Method Investments [Line Items]
Equity method investments			$ 24,121,771		$ 24,121,771		$ 367,970
Gain on equity method investments					32,030	$ 0
Gain on equity method investments			$ 38,323,506	$ 0	38,323,506	0
Percentage of sale of investment in Bioceres, S.A.				71.40%
Net proceeds from sale of equity investment					400,000	$ 988,504
Gain on sale of marketable securities				$ 68,967	$ 32,030
Conterra
Schedule of Equity Method Investments [Line Items]
Settlement of long-term debt principal, interest and other related costs	$ 6,600,000
Shell
Schedule of Equity Method Investments [Line Items]
Proceeds from divestiture of business at closing	$ 7,000,000
Membership interest repurchase percent	6%
Fair market value of purchase option	$ 600,000
Shell \| Minimum
Schedule of Equity Method Investments [Line Items]
Membership interest repurchase price	7,100,000
Shell \| Maximum
Schedule of Equity Method Investments [Line Items]
Additional proceeds to be received from sale of businesses in one year	6,000,000
Membership interest repurchase price	$ 12,000,000
Vision Bioenergy
Schedule of Equity Method Investments [Line Items]
Additional ownership percentage	10%
Fair value of contingent transfers	$ 1,100,000
Ownership interest	34%		34%		34%		0%
Equity method investments	$ 23,700,000		$ 23,340,657		$ 23,340,657
Carrying value of asset and inventory contributed	5,500,000
Fair value of property contributed to llc	12,900,000
Net identifiable assets	18,900,000
Difference between carrying amount and net identifiable assets	4,800,000
Deconsolidation revaluation of retained investment, gain amount	8,600,000
Vision Bioenergy \| Conterra
Schedule of Equity Method Investments [Line Items]
Settlement of long-term debt principal, interest and other related costs	6,800,000
Vision Bioenergy \| Shell
Schedule of Equity Method Investments [Line Items]
Contribution made in exchange for ownership interest	13,200,000
Proceeds from divestiture of business at closing	7,000,000
Fair value of payment based on discounted value	5,747,126		5,747,127		5,747,127
Additional payments made to partnership in exchange for ownership interest	12,000,000
Fair value of additional cash contribution based on discounted value	$ 11,500,000
Membership interest repurchase percent	6%
Fair market value of purchase option	$ 604,000				604,000
Ownership interest	66%
Equity method investments	$ 23,664,195
Member investment in partnership	45,900,000
Aggregate consideration received	43,800,000
Carrying value of asset and inventory contributed	5,532,694		$ 5,532,694		5,532,694
Fair value of intangible contributed to llc	18,100,000
Gain on equity method investments	38,323,506
Equity method investment total valuation amount	69,600,000
Vision Bioenergy \| Shell \| Prepaid Expenses and Other Current Assets
Schedule of Equity Method Investments [Line Items]
Fair value of payment based on discounted value	5,700,000
Vision Bioenergy \| Shell \| Maximum
Schedule of Equity Method Investments [Line Items]
Additional proceeds to be received from sale of businesses in one year	6,000,000
Possible reduction in proceeds to be received from sale of businesses in one year	4,500,000
Vision Bioenergy \| Shell \| Conterra
Schedule of Equity Method Investments [Line Items]
Settlement of long-term debt principal, interest and other related costs	$ 6,840,879				$ 6,840,879
Trigall Australia Pty Ltd
Schedule of Equity Method Investments [Line Items]
Proceeds from sale of interest in subsidiary		$ 2,000,000
Ownership interest		20%	20%		20%		0%
Equity method investments		$ 800,000	$ 781,114		$ 781,114
Carrying value of asset and inventory contributed		2,000,000
Fair value of assets contributed		3,800,000
Gain on equity method investments		1,800,000
Capital contributions to be made		600,000
Trigall Australia Pty Ltd \| Promissory Note
Schedule of Equity Method Investments [Line Items]
Promisory notes to be recieved		1,000,000
Trigall Australia Pty Ltd \| Promissory Note \| Prepaid Expenses and Other Current Assets
Schedule of Equity Method Investments [Line Items]
Proceeds from partnership transaction		$ 1,000,000
Trigall Australia Pty Ltd \| Trigall Genetic S.A
Schedule of Equity Method Investments [Line Items]
Ownership interest		80%
Equity method investments		$ 3,000,000
Fair value of assets contributed		$ 3,800,000
Bioceres
Schedule of Equity Method Investments [Line Items]
Ownership interest			0%		0%		1%
Equity method investments							$ 367,970
Gain on equity method investments					$ 32,030
Percentage of sale of investment in Bioceres, S.A.				71.40%
Net proceeds from sale of equity investment				$ 1,000,000	$ 400,000
Gain on sale of marketable securities				$ 100,000

Investments - Schedule of Gain

Investments - Schedule of Gain on Equity Method Investments (Details) - USD ($)		3 Months Ended		9 Months Ended
	Feb. 06, 2023	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2022
Schedule of Equity Method Investments [Line Items]
Equity investment		$ 24,121,771		$ 24,121,771		$ 367,970
Gain on equity method investments		38,323,506	$ 0	38,323,506	$ 0
Conterra
Schedule of Equity Method Investments [Line Items]
Debt retirement	$ 6,600,000
Shell
Schedule of Equity Method Investments [Line Items]
Cash	7,000,000
Fair value of 6% member purchase option	600,000
Vision Bioenergy
Schedule of Equity Method Investments [Line Items]
Equity investment	23,700,000	23,340,657		23,340,657
Fixed assets and inventory transfer	(5,500,000)
Vision Bioenergy \| Conterra
Schedule of Equity Method Investments [Line Items]
Debt retirement	6,800,000
Vision Bioenergy \| Shell
Schedule of Equity Method Investments [Line Items]
Equity investment	23,664,195
Cash	7,000,000
Present value of future payment	5,747,126	5,747,127		5,747,127
Fixed assets and inventory transfer	(5,532,694)	$ (5,532,694)		(5,532,694)
Fair value of 6% member purchase option	604,000			604,000
Gain on equity method investments	38,323,506
Vision Bioenergy \| Shell \| Conterra
Schedule of Equity Method Investments [Line Items]
Debt retirement	$ 6,840,879			$ 6,840,879

Investments - Schedule of Gai_2

Investments - Schedule of Gain on Equity Method Investments (Parenthetical) (Details) - Shell Oil Products US [Member]	Feb. 06, 2023
Schedule of Equity Method Investments [Line Items]
Membership interest repurchase percent	6%
Vision Bioenergy Oilseeds LLC [Member]
Schedule of Equity Method Investments [Line Items]
Membership interest repurchase percent	6%

Investments - Summary of Financ

Investments - Summary of Financial Information of Unaudited Balance Sheet (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Jun. 30, 2021
Schedule of Equity Method Investments [Line Items]
Cash	$ 1,569,463		$ 2,056,508
Intangible assets	30,328,212		34,095,827			$ 37,130,942
Other assets	2,038,618		1,128,507
TOTAL ASSETS	158,483,654		133,787,851
Current liabilities	71,380,889		48,291,496
Equity	75,724,512	$ 42,051,933	51,408,669	$ 63,817,023	$ 64,160,529	$ 74,393,193
TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' EQUITY	158,483,654		$ 133,787,851
Vision Bioenergy
Schedule of Equity Method Investments [Line Items]
Cash	11,042,929
Other current assets	432,992
Fixed assets	14,385,791
Intangible assets	17,820,005
Goodwill	14,006,268
Other assets	165,796
TOTAL ASSETS	57,853,781
Current liabilities	581,549
Long-term liabilities	117,492
Equity	57,154,740
TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' EQUITY	$ 57,853,781

Investments - Summary of Fina_2

Investments - Summary of Financial Information of Unaudited Income Statement (Details) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Schedule of Equity Method Investments [Line Items]
Revenue	$ 17,662,307	$ 23,186,877	$ 50,465,974	$ 51,349,967
Gross profit (loss)	4,430,471	2,705,414	11,684,273	7,492,447
Loss from operations	(3,912,749)	(6,210,929)	(13,562,196)	(20,877,021)
Net loss	32,119,365	$ (7,304,923)	21,624,419	$ (23,500,000)
Vision Bioenergy
Schedule of Equity Method Investments [Line Items]
Revenue	83,505		83,505
Gross profit (loss)	(206,985)		(206,985)
Loss from operations	(953,718)		(953,718)
Net loss	$ (951,582)		$ (951,582)

Investments - Schedule of Carry

Investments - Schedule of Carrying Amount of The Company's Equity Method Investments (Details) - USD ($)	Mar. 31, 2023	Feb. 06, 2023	Dec. 23, 2022	Jun. 30, 2022
Schedule of Equity Method Investments [Line Items]
Total equity method investments, Carrying Amount	$ 24,121,771			$ 367,970
Vision Bioenergy
Schedule of Equity Method Investments [Line Items]
Total equity method investments, Carrying Amount	$ 23,340,657	$ 23,700,000
Economic Interest	34%	34%		0%
Trigall Australia
Schedule of Equity Method Investments [Line Items]
Total equity method investments, Carrying Amount	$ 781,114		$ 800,000
Economic Interest	20%		20%	0%
Bioceres
Schedule of Equity Method Investments [Line Items]
Total equity method investments, Carrying Amount				$ 367,970
Economic Interest	0%			1%

Series B Convertible Preferre_3

Series B Convertible Preferred Stock - Additional Information (Details)	9 Months Ended
	Mar. 31, 2023 shares
MEZZANINE EQUITY
Temporary Equity [Line Items]
Issuances and conversion of preferred stock to common stock	0

Series B Convertible Preferre_4

Series B Convertible Preferred Stock - Summary of Changes to Series B Convertible Preferred Stock (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2022
Temporary Equity Disclosure [Abstract]
Mezzanine Equity Beginning Balance, amount			$ 4,804,819
Issuance of preferred stock					$ 4,638,521
Dividends accrued	$ 95,299	$ 40,276	271,746	$ 40,276	127,541
Accretion of discount for warrants			77,514	$ 12,919	38,757
Mezzanine Equity Ending Balance, amount	$ 5,154,079		$ 5,154,079		$ 4,804,819

Non-Cash Activities for State_3

Non-Cash Activities for Statements of Cash Flows - Schedule of Condensed Consolidated Statements of Cash Flows for Non-Cash Activities (Details) - USD ($)		3 Months Ended		9 Months Ended		12 Months Ended
	Feb. 06, 2023	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2022
Non-cash investing activities:
ROU assets financed by lease liabilities				$ 498,143	$ 271,524
Consideration received from Shell for equity interest in Vision Bioenergy:
Contribution of intangible assets to Trigall in exchange for equity investment and promissory note				(1,750,000)
Non-cash financing activities:
Warrants issued for financial commitment asset				1,894,901
Dividends accrued for participating securities		$ 95,299	$ 40,276	271,746	40,276	$ 127,541
Accretion of discount for series B preferred stock warrants				77,514	$ 12,919	$ 38,757
Shell Oil Products US [Member]
Consideration received from Shell for equity interest in Vision Bioenergy:
Membership purchase option	$ 600,000
Vision Bioenergy Oilseeds LLC [Member]
Consideration received from Shell for equity interest in Vision Bioenergy:
Contribution of property, plant and equipment and inventory to Vision Bioenergy for equity interest	(5,500,000)
Vision Bioenergy Oilseeds LLC [Member] \| Shell Oil Products US [Member]
Consideration received from Shell for equity interest in Vision Bioenergy:
Note receivable	5,747,126	5,747,127		5,747,127
Membership purchase option	604,000			604,000
Contribution of property, plant and equipment and inventory to Vision Bioenergy for equity interest	(5,532,694)	$ (5,532,694)		(5,532,694)
Conterra [Member]
Consideration received from Shell for equity interest in Vision Bioenergy:
Settlement of long-term debt principal, interest and other related costs	6,600,000
Conterra [Member] \| Vision Bioenergy Oilseeds LLC [Member]
Consideration received from Shell for equity interest in Vision Bioenergy:
Settlement of long-term debt principal, interest and other related costs	6,800,000
Conterra [Member] \| Vision Bioenergy Oilseeds LLC [Member] \| Shell Oil Products US [Member]
Consideration received from Shell for equity interest in Vision Bioenergy:
Settlement of long-term debt principal, interest and other related costs	$ 6,840,879			$ 6,840,879